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Borna  Disease  Virus  and  its  Hosts.  Studies  on  Virus-Host 
Interactions and Virus Detection  
Abstract 
Borna  disease  virus  (BDV)  is  an  RNA-virus  persistently  infecting  the  central 
nervous  system of,  and  thereby  causing  neurological  disorders  in,  several  animal 
species,  possibly  including  humans.  Although  several  aspects  of  BDV  and  its 
pathologies have been studied for more than 100 years, further elucidation of the 
epidemiology and pathogenesis, and the development of reliable detection methods, 
is needed. 
This thesis describes the relationship between BDV and its hosts, with special 
emphasis on virus-host interactions and virus detection. The aims were to improve 
current  detection  methods,  and  to  increase  the  knowledge  of  virus-host 
interactions,  especially  in  naturally  infected  animals.  First,  a  real-time  RT-PCR 
assay  for  BDV  detection  was  developed;  and  second  this  method,  as  well  as 
serology, was evaluated for use when diagnosing Borna disease (BD) in cats. These 
studies suggest that serology is the most useful tool to further strengthen a clinical 
suspicion of feline BD, whereas molecular diagnostics, using blood samples, can be 
added for cats showing mild neurological signs. 
In the third study, phosphorylated BDV P and previously reported BDV-host 
protein-protein  interactions  were  detected  in  cell  cultures,  as  well  as  in 
experimentally and naturally infected animals, by the use of an in situ proximity 
ligation assay. These protein-protein interactions most likely interfere with signaling 
pathways of the host, enabling BDV to establish a persistent infection.  
The type II interferon (IFN- ) is an important key factor of the antiviral host 
immune response, involved in non-cytolytic clearance of BDV. In the final study, 
IFN-  mRNA expression was studied in feline BD. A high expression was seen in 
these cats, as compared to non-infected controls. This expression was higher in cats 
showing mild neurological signs, and in these cats also moderate-severe pathological 
lesions  were  found.  These  data  point  to  more  direct  effects  of  BDV  in  disease 
development than has previously been considered. 
In  conclusion,  this  thesis  provides  an  overview  of  the  current  knowledge  of 
BDV, and contributes novel data on virus-host interactions and virus detection.   
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ABV  Avian Bornavirus 
ANS  Autonomic nervous system 
BD 
BDV 
Borna disease 
Borna disease virus 
cDNA  Complementary DNA 
CNS  Central nervous system 
DNA  Deoxyribonucleic acid 
ELISA  Enzyme-linked immunosorbent assay 
G/GP/gp  Glycoprotein 
GABA   -aminobutyric acid 
GABA-R  GABA-receptor 
GABARAP  GABA-receptor associated protein 
IFA  Immunofluorescence assay 
IFN  Interferon 
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ISH  In situ hybridization 
kDa  kilo Dalton 
L  Large protein, viral RNA-dependent RNA-polymerase 
M  Matrix protein 
N  Nucleoprotein 
NES  Nuclear exportation signal 
NLS  Nuclear localization signal 
ORF  Open reading frame 
P  Phosphoprotein 
PCR  Polymerase chain reaction 
PLA  Proximity ligation assay 
PDD  Proventricular dilatation disease 
RNA  Ribonucleic acid   9 
RNP  Ribonucleoprotein or nucleocapsid 
rRT-PCR  Real-time RT-PCR 
RT-PCR  Reverse transcriptase – PCR 
X  p10 protein, non-structural protein of BDV 
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Introduction 
In  the  18
th  century,  a  neurological  disease  in  horses,  at  that  time  called 
“Kopfkrankheit  der  Pferde”  (head  disease  of  horses),  was  described  in  a 
German textbook (reviewed in the article of Dürrwald & Ludwig, 1997). 
This disease had been known for a long time in Germany, especially in the 
southern  and  southeastern  parts,  where  it  occasionally  occurred  (Zwick, 
1939). After severe losses around the city of Borna (Saxony) in the 1890’s, 
the disease was thereafter known as “Bornasche Krankheit” (Borna disease, 
BD). In 1907, the Ministry of Home Affairs of the Kingdom of Saxony 
decided that the disease should be thoroughly investigated, with the aim to 
characterize its clinical signs, pathology and etiology. The clinical signs and 
pathology were then well characterized by Schmidt in 1912, and by Joest 
and Degen in 1911. Several attempts to establish the etiology behind BD 
were made. At first, bacterial causes of the disease were proposed; however, 
based  on  the  lack  of  presence  of  a  purulent  inflammation,  the  proposed 
cause was changed to a bacterial toxin (reviewed by Zwick, 1939).  
At  the  end  of  the  19
th  century,  the  first  viruses  were  discovered: 
Ivanovsky and Beijerinck described the tobacco mosaic virus, and Loeffler 
and Frosch the first animal virus (foot-and-mouth disease virus) (Murphy et 
al., 1999). The first successful attempts to transmit BD from a diseased horse 
to rabbits were made by Zwick and Seifried in 1924-25 (Zwick & Seifried, 
1925),  and  a  few  years  later  Zwick  and  his  co-workers  had  convincing 
evidence for a viral etiology of BD. 
In  the  early  history  of  BD  research,  studies  of  the  pathogenesis,  viral 
entry and secretion, as well as epidemiology, clinical signs and treatment, 
were in focus. This focus of the BD research has not changed dramatically 
over the last century, but still many questions within these fields have to be 
answered.  This  thesis  contributes  with  improved  detection  methods  and 
novel information about BDV-host interactions.   12 
 
Borna Disease Virus 
Borna disease virus (BDV) was first considered to be the etiological cause of 
BD in 1928. Through successful transfer of filtered brain suspensions from a 
horse  with  BD  to  rabbits,  and  thereafter  by  several  passages  in  rabbits 
(Zwick et al., 1928; Zwick & Seifried, 1925), it was concluded that a virus 
was the causative agent of BD. However, at that time the characteristics of 
viruses and the structures of viral particles (virions) were unknown. 
The characterization of BDV was begun by Zwick and others, especially 
regarding  physical  properties,  and  how  the  virus  could  be  inactivated 
(Zwick, 1939; Nicolau & Galloway, 1928; Zwick et al., 1928). The size was 
established to be around 85-125 µm, values that are still valid today (de la 
Torre,  2002;  Zwick,  1939).  In  the  late  1960’s,  viral  antigens  could  be 
visualized by immunofluorescence (Wagner et al., 1968), and a few years 
later successful cultivation of BDV in tissue culture was performed (Ludwig 
et al., 1973; Mayr & Danner, 1972). It was suggested that BDV was an 
RNA-virus (Danner, 1977; Ludwig & Becht, 1977), mainly associated with 
the infected cells and only to a minor extent released from the cells (Ludwig 
& Becht, 1977). The first electron micrographs showed spherical particles 
(Ludwig & Becht, 1977), which was later confirmed (Kohno et al., 1999; 
Zimmermann et al., 1994a). For a long time, the sequence and organization 
of the virus genome was unknown. It was not until the 1990’s that the first 
full-genome  sequences,  and  the  organization  of  the  BDV  genome,  were 
established (Briese et al., 1994; Cubitt et al., 1994a). 
Genome Organization 
BDV is a non-segmented, non-enveloped virus with a genome of single-
stranded negative sense RNA of around 8900 nucleotides in length (Lipkin 
& Briese, 2006; Briese et al., 1994; Cubitt et al., 1994a). On the basis of its 
unique nuclear site of replication, compared to other animal viruses within 
the order of Mononegavirales (Briese et al., 1992), BDV is the sole member of 
the Bornaviridae family. The genome is organized in a similar manner to 
other  members  of  the  order  of  Mononegavirales,  i.e.  N,  P,  M,  G  and  L 
(Figure 1). In addition, like most members of the Paramyxoviridae family, 
BDV has a small non-structural gene, designated X, which is located as an 
over-lapping open reading frame (ORF) together with the P gene (Pringle, 
2005; Jordan & Lipkin, 2001).   13 
BDV  has  three  transcription  units  that  encode  six  ORFs  (Jordan  & 
Lipkin, 2001), and exploits the cellular splicing mechanisms to efficiently 
use  its  comparatively  short  genome  (Figure  1)  (Cubitt  et  al.,  1994b; 
Schneider et al., 1994). The first ORF in the first transcription unit results in 
the nucleoprotein (N), whereas the second transcription unit contains two 
overlapping ORFs for the phosphoprotein (P), and the p10 or X protein 
(Tomonaga et al., 2002; Jordan & Lipkin, 2001). The third transcription 
unit is spliced differently, and also has different transcription initiation and 
termination signals, enabling polymerase read-through during transcription, 
which results in expression of the matrix protein (M), the glycoprotein (G), 
and the large protein or RNA-dependent RNA-polymerase (L) (Tomonaga 
et al., 2002; Jordan & Lipkin, 2001). 
 
Figure 1. Map of genome organization and protein-coding mRNA transcripts of BDV. The 
BDV genome is comparatively short, and therefore BDV uses alternative transcription 
strategies, like over-lapping ORFs and usage of host cellular splicing mechanisms. Modified 
from Tomonaga et al., (2002).  
 
The genome of BDV is highly conserved, and so far two genotypes have 
been observed with approximately 15% differences at the nucleotide level 
(Nowotny et al., 2000). Some observations indicate that BDV isolates cluster 
into  separate  geographical  regions  based  on  their  genetic  composition 
(Kolodziejek  et  al.,  2005),  though  other  studies  have  not  confirmed  this 
(Bode, 2008; Wensman et al., 2008). The conserved genome has led to the 
conclusion that BDV is an evolutionarily old virus, which has further been 
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supported  by  recent  findings  of  BDV-like  elements  in  the  genome  of 
different mammals including the human genome (Belyi et al., 2010; Horie et 
al., 2010). 
Recently, a more divergent Bornavirus with similar genome organization 
has been detected in psittacine birds, designated Avian Bornavirus (ABV) 
(Honkavuori et al., 2008; Kistler et al., 2008). 
 
Viral Proteins 
The six polypeptides encoded in the BDV genome each have important 
functions in the viral life cycle. 
Nucleoprotein 
The nucleoprotein (N) is the most abundant viral protein, and is mainly 
located inside the nucleus (de la Torre, 2002). Besides the genomic RNA, 
N is the main component of the nucleocapsid or ribonucleoprotein (RNP) 
complex. BDV N and the BDV-RNA form polymers (Hock et al., 2010), 
together forming the backbone of the RNP.  
BDV N also interacts with P (Berg et al., 1998b), and has an important 
role, together with P, in the intracellular transport of the RNPs to and from 
the nucleus (Kobayashi et al., 2001). 
Phosphoprotein 
In  other  negative-stranded  non-segmented  RNA-viruses,  the 
phosphoprotein (P) is an important co-factor to the polymerase complex in 
the processes of transcription and replication. However, unlike these other 
viral  phosphoproteins,  BDV  P  down-regulates  the  activity  of  the  viral 
polymerase  upon  phosphorylation  (Schmid  et  al.,  2007).  The 
phosphorylation of P is still needed for efficient viral spread in infected cells 
(Schmid  et  al.,  2010),  indicating  important  functions  of  P  in  viral 
transmission. 
BDV P is phosphorylated at serine residues mainly by protein kinase C  
(PKC ), but to a lesser extent also by casein kinase II (CKII) (Schwemmle et 
al., 1997). In infected cells, P forms homomers, either as tri- or tetramers 
(Hock et al., 2010; Schneider et al., 2004). The phosphorylated P multimer 
can interact with L (Walker et al., 2000); however, N not bound to the 
RNP complex can block this interaction (Schneider, 2005). 
BDV P can also interact with X (Schwemmle et al., 1998), and does so 
preferably  as  a  monomer,  which  indicates  that  X  plays  a  role  in 
multimerization of P (Schneider, 2005).   15 
Matrix Protein 
The matrix protein (M) of BDV composes a shell or an outer layer of the 
RNP,  likely  protecting  the  genomic  RNA  and  the  other  nucleocapsid 
proteins. BDV M forms tetra- or octamers (Kraus et al., 2005; Stoyloff et al., 
1997), which are a part of the RNP complex by interaction with P without 
inhibitory effects of the polymerase activity (Chase et al., 2007). Moreover, 
M  binds  to  single-stranded  RNA  and  interacts  with  lipid  membranes 
(Neumann et al., 2009), suggesting a key role in assembly of RNPs and viral 
particles similar to other negative-stranded RNA-viruses.  
Antibodies towards M neutralize BDV infectivity (Stoyloff et al., 1998; 
Hatalski  et  al.,  1995), indicating  that  M  is  present  on  the  surface  of  the 
infectious virus particle. However, BDV also spreads as RNPs, from cell to 
cell inside the CNS as well as in cell culture (Clemente & de la Torre, 2007; 
de la Torre, 2002; Gosztonyi et al., 1993). Hence, the neutralizing effect of 
anti-M antibodies most likely is due to neutralization of infectious RNPs. 
Glycoprotein 
Glycoproteins  (G)  of  viruses  are  membrane  proteins  important  for  viral 
attachment to cellular receptors and viral entry into the host cell.  
In BDV, G is a glycosylated protein with a molecular weight of about 94 
kDa (gp94) (Schneider et al., 1997), which is a precursor molecule needed 
to  be  cleaved  by  the  cellular  protease  furin  into  two  biologically  active 
proteins,  GP-1  and  GP-2  (Richt  et  al.,  1998).  GP-1  is  responsible  for 
attachment to the host cell surface by binding of (a) yet unidentified cellular 
receptor(s)  (Clemente  et  al.,  2010;  Perez  et  al.,  2001).  However,  one 
potential  player  is  BiP  (immunoglobulin  heavy  chain-binding  protein), 
which  is  an  endoplasmic  chaperone  also  expressed  on  the  cell  surface 
(Honda et al., 2009). Upon receptor binding, BDV is taken up by the host 
cell through endocytosis (Clemente & de la Torre, 2009; Perez et al., 2001). 
In  the  early  endosome  inside  the  cytoplasm,  GP-2  mediates  the  pH-
dependent fusion of the viral and endosomal membranes to release the RNP 
(Clemente & de la Torre, 2009; Gonzalez-Dunia et al., 1998). Antibodies 
against  BDV  G  have  neutralizing  activity  (Gonzalez-Dunia  et  al.,  1997; 
Schneider et al., 1997). 
Large Protein or RNA-Dependent RNA-Polymerase 
The large (L) protein of BDV is an RNA-dependent RNA-polymerase of 
around 190 kDa (Walker et al., 2000). L has the possibility to translocate 
into the nucleus by itself (Walker & Lipkin, 2002; Walker et al., 2000), 
though other viral proteins within the RNP further facilitate this nuclear   16 
translocation (de la Torre, 2002). Cellular kinases phosphorylate L, which 
probably is a part of the regulation of the polymerase activity (Walker et al., 
2000). 
For successful transcription and replication, several BDV proteins (N, P, 
and L) are needed to form a polymerase complex (Schneider, 2005). The 
model for how this complex works, is most likely the same as that proposed 
for other non-segmented negative-stranded RNA-viruses, like Sendai virus 
(Hock et al., 2010; Schneider, 2005; Curran, 1998). Phosphorylated BDV P 
negatively regulates the activity of the polymerase complex (Schmid et al., 
2007), which could be contributed by the binding of X to P (see below; 
Poenisch et al., 2004). 
  
 
Figure 2. Apoptosis resistance in BDV-infected C6 cells, but not in BDV-infected Vero cells 
after H2O2 treatment. Cells were either mock-treated (0) or treated with 500 (C6) or 750 
(Vero) µM of H2O2 for 48 h, harvested and incubated with Annexin V antibody (apoptotic 
cell marker) and propidium iodide (necrotic cell marker). Subsequently, fluorescent activated 
cell  sorting  (FACS)  was  performed,  and  the  ratio  of  apoptotic  cells  (R)  then  calculated 
according to the equation R=([necrotic+apoptotic cells]+apoptotic cells)/living cells. The 
asterisks indicate statistically significant differences (two-tailed t-test), where * is p<0.05, and 
*** p<0.001. 
X Protein 
Like other members of the order of Mononegavirales (Pringle, 2005), BDV 
also expresses a small non-structural or accessory protein (Schwardt et al., 
2005). This protein is called X or p10, based on its molecular weight of 10 
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kDa, and co-localizes in the nucleus together with N and P (Wehner et al., 
1997), by interaction with P (Wolff et al., 2000; Schwemmle et al., 1998). 
BDV X seems to be a multifunctional protein. Besides its involvement in 
the regulation of the polymerase complex activity (Poenisch et al., 2008; 
Poenisch  et  al.,  2007;  Poenisch  et  al.,  2004),  X  also  inhibits  apoptosis, 
thereby  promoting  a  persistent  infection  (Poenisch  et  al.,  2009).  The 
mechanism for this apoptosis resistance is as yet unknown, though X seems 
to have to localize to the mitochondrion to exercise this resistance (Poenisch 
et al., 2009). 
However,  there  are  cell  line  differences  in  the  X-induced  apoptosis 
resistance of BDV-infected cells. In a rat astrocytoma (C6) cell line, BDV-
infected cells are clearly resistant to apoptosis stimuli (Figure 2, left diagram; 
Poenisch  et  al.,  2009),  whereas  a  green  monkey  kidney  (Vero)  cell  line 
shows no BDV-induced apoptosis resistance (Figure 2, right diagram). 
BDV-Like Elements in Mammalian Genomes 
Some viruses are known to be able to insert parts of their genomes into the 
genomic DNA of the host. For some viruses, like retroviruses, this strategy 
is  needed  for  their  replication.  Other  viruses,  like  herpesviruses  and 
parvoviruses,  most  likely  use  this  capacity  as  a  means  to  avoid  the  host 
immune response, by establishing a form of latent or persistent infection 
(Liu et al., 2011; Morissette & Flamand, 2010), but it could also be a way to 
exchange  genetic  material.  The  integration  of  viral  genes  into  the  host 
genome can lead to different pathological changes, such as tumor formation, 
and possibly even autoimmunity (Morissette & Flamand, 2010). During the 
course of evolution, viral hosts likely have gained new genes, beneficial for 
their  survival,  through  this  gene  exchange,  either  by  getting  novel 
functional proteins and/or as a way to acquire immunity to these viruses 
(Koonin, 2010).  
Until recently, only retroviruses and DNA-viruses were known to have 
the  ability  to  incorporate  into  the  genome  of  the  host  cell.  BDV-like 
elements  have  now  been  found  integrated  into  the  genome  of  different 
mammals, including humans (Belyi et al., 2010; Horie et al., 2010). These 
integration events happened millions of years ago (Belyi et al., 2010; Horie 
et  al.,  2010),  though  they  can  also  occur  in  acute  infection  of  different 
animals (Kinnunen et al., 2011; Horie et al., 2010). Furthermore, elements 
from  other  RNA-viruses  within  the  order  of  Mononegavirales,  Ebola  and 
Marburg viruses, have also been found incorporated into the genomes of 
mammalian  hosts  (Belyi  et  al.,  2010).  Some  of  these  elements  result  in 
protein expression (Belyi et al., 2010; Horie et al., 2010). These findings   18 
have led to renewed discussions about the relationship between BDV and 
possible human infections (Kinnunen, 2011; Feschotte, 2010; Tomonaga, 
2010). 
Diseases Caused by Bornaviruses 
Most mammals and birds seem to be susceptible to BDV infection, although 
not  all  experimental  infections  are  followed  by  disease.  Infection  occurs 
naturally in most mammals, as well as in birds. In the following sections, the 
most  common  natural  host  species  of  BDV  leading  to  disease  will  be 
described. Experimental infection in rats will also be discussed briefly. 
Borna Disease in Horses, Sheep and Cattle 
The horse was the first recognized host species of BDV, and it was from 
brain tissues from horses with BD that Zwick and his co-workers could 
infer a viral etiology (Zwick, 1939; Zwick et al., 1928; Zwick & Seifried, 
1925).  Around  the  same  time,  BDV  was  found  in  sheep  and  cattle 
(reviewed in Zwick, 1939; Nicolau & Galloway, 1928). Before the etiology 
of  BD  was  determined,  the  clinical  signs  in  horses  were  carefully 
characterized  (Schmidt,  1912).  This  thorough  investigation  of  over  400 
cases, as well as similar recent studies by others (reviewed in Heinig, 1969; 
Richt  et  al.,  2000;  Ludwig  et  al.,  1985),  have  established  the  following 
clinical signs: 
The early signs of BD are disturbances in feed intake, like arrested eating, 
fever and different degrees of somnolence. Mild colic signs and/or irregular 
defecation, alternately with constipation and diarrhea, are commonly seen. 
In stallions and geldings, a continuously prolapsed penis without urination is 
common (Figure 3). Hypersensitivity and muscular twitches occur in both 
the head and extremities, as well as gait disturbances and hesitation when 
jumping over hurdles. 
These  signs  become  progressively  aggravated  over  the  following  days. 
The sick horse gets more somnolent, with abnormally lowered head most 
often pressed against the wall or supported by the crib, and its eyes closed 
(Figure 4, to the right). The gait disturbances get more pronounced, and if 
the horse is allowed to move at will it frequently moves in circles, always in 
the same direction (Figure 4, to the left). If the legs are manipulated, horses 
with  BD  will  sometimes  keep  standing  with  over-crossed  legs  without 
trying  to  make  corrections,  indicating  postural  deficits.  Muscular 
convulsions  are  common,  for  example  in  the  chewing  muscles,  causing 
bruxism  and  problems  with  feed  intake.  Involuntary  eye  movements   19 
(nystagmus),  different  sized  pupils  and  blindness  are  also  common  signs 
(Richt et al., 2000; Heinig, 1969; Schmidt, 1912).  
 
 
Figure  3.  Horse  with  clinical  signs  of  BD.  The  horse  shows  apathy,  weight  loss,  and  a 
continuously prolapsed penis, all typical signs of BD. Received from Hanns Ludwig, Berlin, 
Germany. 
In the end-stage, muscles of the head and extremities get paralyzed. Paralysis 
is usually the cause of death, by hindering feed and water intake (paralysis of 
the tongue, chewing, and/or swallowing muscles), and/or by immobilizing 
the  animal.  Fever  is  also  seen  frequently  in  the  end-stage  of  the  disease 
(Schmidt,  1912).  More  atypical  and  milder  clinical  signs,  like  recurrent 
colic, gait disturbances and behavioral changes, connected to BDV-infection 
have  also  been  reported  (Berg  et  al.,  1999a;  Bode  et  al.,  1994a).  The 
duration of disease is mostly 1-3 weeks, but longer durations can be seen 
(Heinig,  1969).  In  some  cases,  complete  or  partial  recovery  occurs 
spontaneously,  sometimes  followed  by  relapses  and  death  (Heinig,  1969; 
Schmidt, 1912). The prognosis of BD is usually considered to be bad, and a 
mortality rate of 75-95% has been described (Heinig, 1969).   20 
 
Figure  4.  Horses  showing  typical  clinical  signs  of  BD.  Left:  A  pony  showing  circular 
movement. Ponies and haflingers seem to be more susceptible to BDV-infection, and show 
more  severe  signs  with  faster  progression  (Liv  Bode  and  Hanns  Ludwig,  personal 
communication).  Right:  A  horse  with  BD  in  the  end-stage  of  the  disease.  This  horse  is 
somnolent with lowered head, and head injuries after throwing it against the wall. This horse 
was positive for BDV by FACS analysis (Bode et al., 1994c). Received from Hanns Ludwig, 
Berlin, Germany. 
However,  reports  where  novel  diagnostic  methods  have  been  used  for 
detection of antibodies and/or antigen have questioned the high mortality 
rate of BD, since many horses seem to have sub-clinical or atypical BDV-
infection (Bode, 2008; Dieckhöfer, 2008; Ludwig & Bode, 2000; Berg et 
al., 1999a). 
In sheep, a similar clinical picture is seen as for horses, although up to 
20% of a herd can develop the disease, while only sporadic cases occur in 
horse  stables  (Ludwig  &  Kao,  1988).  Early  signs  in  sheep  are  social 
behavioral  changes  and  apathy  (Heinig,  1969).  Hyperesthesia  in  the 
lumbosacral region is also common. As the disease progresses, decreased feed 
intake, bruxism and circular movement are seen (Figure 5). The incubation 
time is several weeks, and the duration of disease is around 4-10 days, with 
around 90% mortality (Ludwig & Kao, 1988; Heinig, 1969). 
Besides  the  initial  reports  of  BD  in  cattle  (Zwick,  1939;  Nicolau  & 
Galloway, 1928), demonstrated by transmission of the disease to laboratory 
animals, there seems to be only sporadic occurrence in this species. Hence, 
BDV-infection of cattle has been considered as a possible event (Mayr & 
Danner, 1978). In more recent cases, similar clinical signs as for horses and 
sheep have been reported, such as decreased feed intake, gait disturbances 
including circular movement, and finally in some cases paresis or paralysis 
(Okamoto et al., 2002a; Bode et al., 1994b; Caplazi et al., 1994).   21 
BD  has  also  been  observed  in  other  ungulates  (donkeys,  mules  and 
hinnies), as well as in goats and rabbits, with similar signs as for horses and 
sheep (Caplazi et al., 1999; Metzler et al., 1978; Heinig, 1969). 
 
 
 
 
Figure 5. Sheep with BD in the end-stage 
of  the  disease.  This  sheep  is  severely 
ataxic  and  paretic.  The  same  sheep  is 
shown from another angle in Figure 5 of 
Ludwig & Bode (2000). Received from 
Hanns Ludwig, Berlin, Germany. 
 
Bornavirus Infection in Birds 
Recently, two research groups in the United States independently found a 
BDV-like virus in psittacine birds suffering from proventricular dilatation 
disorder  (PDD),  designated  Avian  Bornavirus  (ABV)  (Honkavuori  et  al., 
2008; Kistler et al., 2008). The genome organization of ABV is similar to 
that  of  BDV.  Recently,  successful  experimental  infection  with  an  ABV 
isolate  of  two  different  bird  species  has  been  reported,  thereby  fulfilling 
Koch’s postulates (Payne et al., 2011; Gray et al., 2010). 
PDD is a devastating disease in wild and captive exotic birds, previously 
known as macaw wasting disease, where the birds show gastrointestinal (GI) 
and/or neurological signs (Gregory et al., 1994). The pathology is mainly 
characterized as a lymphocytic inflammation of the ganglia of the GI tract 
and/or CNS. The most common clinical signs are depression, weight loss, 
passage  of  undigested  feed  in  the  feces,  gait  disturbances,  seizures,  and 
decreased or absent postural reactions. 
Not all birds positive for virus and/or antibodies develop disease, but 
instead  can  be  healthy  carriers  and  transmitters  of  ABV  (Hoppes  et  al., 
2010). The routes of transmission are likely to be fecal-oral, but air-borne 
transmission could also occur. ABV-RNA has been found in nasal, choanal, 
and cloacal swabs, as well as in feces and in feathers. However, only feces 
has been confirmed to contain infectious virus, because mallards that had 
eaten fecal droppings from infected cockatiels two weeks later shed viral 
RNA in their feces (Hoppes et al., 2010).   22 
BDV-Infection in Wildlife 
A few wildlife species have been shown to be susceptible to BDV-infection 
followed by clinical signs, and even more species have been shown to carry 
virus  (viral  RNA  and/or  antigen),  or  BDV-specific  antibodies  without 
obvious  clinical  signs.  The  latter  group  will  be  discussed  more  in  detail 
below, in their role as potential BDV reservoirs.  
The first note of BD or a BD-like disease in wildlife was reported from 
Germany  in  the  early  20
th  century  (Zwick,  1939;  Nicolau  &  Galloway, 
1928).  A  deer  was  showing  strange  behavior  when  a  hunter  was 
approaching,  and  was  subsequently  shot.  At  necropsy,  the  typical 
histological  lesions  of  BD  were  found,  including  the  presence  of  intra-
nuclear Joest-Degen inclusion bodies.  
In Sweden, a free-ranging lynx was shot because of its abnormal behavior 
(Degiorgis et al., 2000). At necropsy, a non-purulent inflammation of the 
CNS was found. Neurons and glial cells were positive for BDV-RNA and 
BDV-antigen, using in situ hybridization (ISH) and immunohistochemistry 
(IHC).  Furthermore,  BDV-RNA  was  found  by  RT-PCR,  and  partial 
sequence  analysis  revealed  a  close  genetic  relationship  to  other  Swedish 
BDV strains (96.2-97.7% amino acid identity), as well as to laboratory strains 
(98.5% amino acid identity), yet differences were present (Wensman et al., 
2008; Degiorgis et al., 2000). 
Experimental BDV-Infection in Rats 
Depending on the age and immune-competence of the rat, as well as the 
passage  number  of  the  virus,  the  outcome  of  BDV-infection  is  highly 
variable (Gosztonyi & Ludwig, 1995). In newborn rats, BDV-infection leads 
either to persistent infection with mild behavioral changes, with or without 
an  inflammatory  reaction,  or  to  progressive  neurological  signs  with  fatal 
outcome in the absence of inflammation, depending on the passage number 
and the species used for virus adaptation. In weanlings and adult rats, acute 
encephalitis  with  the  classical  neurological  signs  of  BD  is  seen,  and  the 
animals  die  within  1-4  months.  However,  around  5-10%  of  these  rats 
survive  the  acute  disease,  and  develop  obesity  and  aggressive  behavior 
(Ludwig, 2008; Carbone et al., 1987; Ludwig et al., 1985; Hirano et al., 
1983). Upon intranasal infection, weanlings and adult rats develop an acute 
or  sub-acute  disease,  with  a  severe  inflammatory  infiltration.  In  natural 
infection and upon experimental infection of adult rats, BDV shows no or 
just a few signs of cytopathogenicity; most neurons are intact despite a heavy 
inflammation.  However,  in  persistent  infection  BDV  causes  severe 
pathological  alterations  of  certain  parts  of  the  brain,  thereby  showing   23 
cytopathic effects. Thus, BDV has dual capacities: to induce cell death and 
neuronal degeneration, and persistence without obvious damage to the host 
cells. 
Borna Disease in Cats and Dogs 
In the 1970’s, a fatal neurological disorder in cats was reported from certain 
parts of Sweden (Kronevi et al., 1974). The clinical signs were characterized 
by gait disturbances (Figure 6), such as ataxia and staggering movement, and 
by behavioral changes; thereby the disease got known as staggering disease 
(Sw.  vingelsjuka).  A  viral  etiology  was  suspected,  because  of  the  non-
purulent inflammation of the CNS, and thus thorough efforts to isolate a 
virus  were  made.  However,  the  etiology  remained  unknown  until  the 
1990’s,  when  antibodies  towards  BDV  were  found  in  diseased  cats 
(Lundgren & Ludwig, 1993). This finding pointed towards BDV-infection, 
which was further supported by the pathological lesions found in the same 
regions of the CNS as previously found in, for example, horses with BD 
(Lundgren, 1992; Gosztonyi & Ludwig, 1984). 
 
 
 
 
 
 
 
 
Figure  6.  Cat  with  staggering  disease  or 
feline  BD.  The  cat  was  severely  ataxic, 
and  without  support  it  fell  over  on  its 
side. This cat is included in Paper II and 
IV. Photo: Jonas J Wensman. 
 
Moreover, clinical signs are strikingly similar to BD in horses and sheep: 
initially cats have fever, apathy and reduced appetite, followed by staggering 
and circling movements, behavioral changes, and finally, after a duration of 
1-4 weeks, paresis and/or paralysis (Lundgren, 1992; Kronevi et al., 1974). 
Other minor signs in common with horses, like constipation and impaired   24 
vision, are also seen. However, a clear etiology was not established until a 
feline BDV was isolated (Lundgren et al., 1995b), and used in experimental 
infection  in  cats,  inducing  similar  clinical  signs  and  pathological  lesions, 
thereby fulfilling the postulates of Koch (Lundgren et al., 1997). Since then, 
BDV-RNA, -antigen, and/or BDV-specific antibodies have been found in 
cats with staggering disease, further strengthening the etiology (Wensman et 
al., 2008; Johansson et al., 2002; Berg & Berg, 1998). 
Atypical clinical signs have also been reported (Berg & Berg, 1998). In 
this  case,  a  cat  had  muscular  fasciculation,  after  a  short  initial  period  of 
reduced appetite and apathy. After a few weeks, the signs progressed and the 
cat showed decreased postural reactions. Upon histological investigation, no 
inflammatory reaction was seen inside the CNS, although BDV-RNA was 
found in situ and by RT-PCR. 
Cases of full or partial recovery are also seen, mostly followed by relapses 
(Hultin  Jäderlund,  2003;  Lundgren,  1995).  In  a  few  cases,  an  obesity 
syndrome in recovered cats has been observed (Lundgren, 1995), similar to 
what is seen in experimentally infected rats (Ludwig et al., 1985). 
Staggering  disease  or  similar  neurological  disorders  have  also  been 
reported in other countries (Kamhieh & Flower, 2006). In Austria, cats with 
staggering disease were sero-positive for BDV (Nowotny & Weissenböck, 
1995). Brain suspensions from those cats were inoculated into rabbits, which 
sero-converted but did not develop signs of BD. Later, BDV-RNA was also 
found in an Austrian cat (Berg & Berg, 1998).  
BDV-infection has been found in dogs showing neurological signs, but 
only two cases have been scientifically reported (Okamoto et al., 2002b; 
Weissenböck et al., 1998). In the Austrian case, the dog was fatigued and 
had  a  loss  of  appetite,  followed  by  severe  undefined  neurological  signs 
(Weissenböck et al., 1998). In the case from Japan, the dog initially showed 
hypoesthesia  and  tremor,  and  after  10  days  presented  with  circling 
movement, dilated pupils and salivation (Okamoto et al., 2002b). In both 
cases, a non-purulent inflammation of the CNS was seen, and BDV-antigen 
and –RNA were found in cells. Even though these reports show that dogs 
can be infected by BDV and develop clinical signs, BDV-infection in dogs 
needs to be further scrutinized. 
To my knowledge, at least two dogs have been sero-positive for BDV in 
Sweden. These dogs were presented with gait disturbances.   25 
Pathogenesis of BDV 
Based on the careful characterization of the pathology of BD in horses, Joest 
and Degen proposed already in the early 20
th century that BDV enters the 
CNS through the olfactory epithelium and olfactory nerve (Joest & Degen, 
1911). They also suggested that the virus spreads from neuron to neuron. 
Some years later, Zwick and his co-workers proposed that BDV is not only 
taken up by the olfactory epithelium, but also secreted from there (Zwick et 
al., 1928). They successfully transmitted BDV from suspensions of olfactory 
epithelium, taken from experimentally infected rabbits at the end-stage of 
the disease, to naïve rabbits by intra-cerebral injection. In addition, nasal 
secretions  from  an  experimentally  infected  horse  were  transferred  intra-
nasally  to  a  rabbit.  This  rabbit  developed  mild  clinical  signs  and  mild 
pathological  lesions,  and  brain  suspension  from  this  rabbit  successfully 
transmitted the disease to other rabbits in two passages. Taken together, this 
pioneering work in the first decades of the 20
th century, clearly showed that 
BDV  most  likely  enters  into  neural  cells  of  the  olfactory  epithelium,  is 
transported  via  the  olfactory  nerve,  and  also  is  transported  back  to  the 
olfactory epithelium from the CNS and secreted in the nasal secretions of 
infected animals. 
More recent studies confirm that BDV most likely enters the nervous 
system through the open nerve-endings in the olfactory epithelium and/or 
oro-pharyngeal  mucosa  (Sauder  &  Staeheli,  2003;  Morales  et  al.,  1988). 
Viral  entry  through  nerves  in  the  gastrointestinal  system  has  also  been 
discussed (Heinig, 1969), based on successful experimental oral infections. 
Cell entry occurs through the binding of GP1 to a cellular receptor, which 
guides clathrin-mediated endocytosis (Clemente & de la Torre, 2009; Perez 
et al., 2001; Gonzalez-Dunia et al., 1998). Thereby, BDV is taken up by the 
cell through encapsulation into endosomes, and can be released as RNPs 
from  the  early  endosome  by  a  pH-dependent  fusion  mediated  by  GP2 
(Clemente & de la Torre, 2009; Gonzalez-Dunia et al., 1998). How the 
RNPs  are  transported  to  the  replication  site  inside  the  nucleus  is  not 
known. Even though the exact cellular receptor, to which BDV GP1 binds, 
has not yet been identified, several host factors important for viral entry 
have been recognized (Clemente et al., 2010). Among these are some cell 
surface proteins, for example a subunit of certain GABA-receptors. Whether 
these in vitro findings reflect the situation in infected animals needs further 
elucidation. 
BDV probably uses the axonal transport system of macromolecules for 
transport to the CNS, and reaches the olfactory bulb around 4-6 days after 
experimental intra-nasal infection (Gosztonyi, 2008; Gosztonyi & Ludwig,   26 
1995; Carbone et al., 1987). Thereafter, BDV antigen can be detected along 
the higher olfactory pathways within the limbic system, later disseminating 
to  the  entire  cortical  area  (Gosztonyi,  2008).  Inside  the  CNS,  the  viral 
spread is trans-neural, most likely through RNPs, and not as whole virus 
particles  (Clemente  &  de  la  Torre,  2007;  Gosztonyi  et  al.,  1993).  The 
glutamate kainate 1 (KA-1) receptor has been proposed as the BDV receptor 
in  CNS  (Gosztonyi,  2008;  Gosztonyi  &  Ludwig,  2001).  Clinical  disease 
appears  when  viral  antigens  are  expressed  in  the  neurons  of  the 
hippocampus, along with an inflammatory reaction (Carbone et al., 1987). 
Therefore, the incubation time depends on the route of infection. In an 
experimental intra-nasal infection of rats, the incubation time was around 20 
days (Carbone et al., 1987), whereas it in horses can take up to six months 
(Mayr  &  Danner,  1974).  The  infectious  dose  likely  contributes  to  the 
incubation time. 
One to two months after experimental intra-nasal infection, BDV starts 
to spread centrifugally to the spinal cord, and to the cranial and peripheral 
nerves,  including  nerves  of  the  autonomic  nervous  system  (ANS) 
(Gosztonyi, 2008; Gosztonyi & Ludwig, 1995). BDV also spreads to retinal 
neurons, causing neuronal degeneration, which leads to blindness (Dietzel et 
al., 2007). From the nerves of ANS, more or less every visceral organ gets 
infected after another one or two months. There, BDV actively replicates, 
which  results  in  secretion  of  infectious  virus  particles  (Gosztonyi,  2008; 
Gosztonyi  &  Ludwig,  1995).  For  example,  infectious  BDV  has  been 
detected in lacrimal and nasal secretions of naturally infected horses (Richt et 
al., 2000), urine of experimentally infected rabbits (Zwick, 1939) and rats 
(Gosztonyi,  2008;  Sauder  &  Staeheli,  2003),  in  saliva  of  experimentally 
infected horses and rabbits (Zwick, 1939), and in milk of experimentally 
infected rabbits (Zwick, 1939). 
Virus-Host Interactions 
Immune Responses of the Host 
When a virus infects a host cell, a cascade of different actions starts in order 
to  minimize  the  effects  of  the  intruder.  Among  these  first  actions  is  the 
shutdown of DNA and RNA synthesis, as well as translation of proteins, 
thereby obstructing virus replication and production of viral proteins, which 
the virus uses to interfere with different signaling pathways in the host (see 
below). The host cell also produces different cytokines (signal molecules), 
which bind to receptors of neighboring cells (paracrine) and also to the same   27 
cell (autocrine), to induce an antiviral state, thus reducing the possibility for 
viral infection to spread (Garcia-Sastre & Biron, 2006).  
Upon infection, the type I interferons, IFN-  and IFN- , are important 
key  signal  molecules  in  this  first  line  of  defense  (the  innate  immune 
response), where IFN-  is the most important in the CNS, because of the 
neurotoxicity of IFN-  (Griffin, 2003). Type I IFNs induce the expression 
of  hundreds  of  genes,  resulting  in  different  host  defense  mechanisms  to 
infection. Some of these actions result in death of infected cells (cytolysis), 
to reduce and control an infection (Chawla-Sarkar et al., 2003). The CNS is 
sensitive to cytolytic virus clearance, as many neurons are non-renewable 
and essential for the organism. Hence, non-cytolytic ways of clearing a viral 
infection are important within the CNS (Griffin, 2003; Chesler & Reiss, 
2002). Neurons seem to have specific defense mechanisms, driving a viral 
infection to be non-cytopathic, and stimulating the host immune response 
to follow non-cytolytic clearance (Patterson et al., 2002). For example, host 
neurons reduce or block the budding of viral particles, which can result in 
cytolysis, and viruses have evolved trans-synaptic, non-cytolytic spread of 
RNPs to evade this response of the host. 
 The second line of defense (the adaptive immune response) is composed 
of two main pathways: the humoral immunity, characterized by antibody 
production,  and  cell-mediated  immunity,  consisting  of  T  cells.  The 
cytokines produced initially by the innate immune response attract cells of 
the adaptive immunity, such as natural killer (NK) cells, CD4+ and CD8+ 
T cells, and monocytes/macrophages, first to the perivascular tissues, and 
then also to the brain parenchyma (Griffin, 2003). These immune cells are 
important  for  the  non-cytolytic  clearance  of  viruses,  although  different 
mechanisms are of varying importance when clearing viruses from different 
cells  of  the  CNS.  In  neurons,  virus  clearance  is  mainly  carried  out  by 
antibodies, locally produced by B cells, and IFN- , produced by T cells and 
neurons.  T  cells  in  combination  with  IFN-   are  responsible  for  viral 
clearance of glial cells. Even though virus clearance by these mechanisms 
can be effective, viruses can still persist. 
A  heavy  inflammation  with  cytokine  expression  affects  the  normal 
functions  of  the  CNS  adversely,  and  can  produce  different  neurological 
signs, including behavioral changes (Capuron & Miller, 2011). Natural BDV 
infection, and experimental infection of immune-competent animals, leads 
to the induction of a T cell immune response (Stitz et al., 1995). Thereby, 
BD  is  considered  to  be  an  immune-mediated  disease,  though  increasing 
evidence  points  towards  direct  virus-induced  clinical  signs  as  well  (see 
below).   28 
In perivascular cuffs of experimentally infected rats, CD4+ T helper cells 
are the most common cell type, whereas cytotoxic CD8+ T cells are more 
common in the brain parenchyma (Stitz et al., 2002; Hatalski et al., 1998; 
Deschl et al., 1990). Antibodies, locally produced by plasma cells, can be 
detected (Deschl et al., 1990), and are probably involved in virus clearance. 
IFN-   mRNA  is  expressed,  especially  in  acute  infection  (Hatalski  et  al., 
1998) but also in the chronic phase (Shankar et al., 1992), and is crucial for 
CD8+ T cell-mediated clearance of BDV in experimentally infected mice 
(Hausmann et al., 2005). 
A similar picture is seen in naturally infected horses and cats, which are 
the  only  natural  hosts  of  BDV  where  the  immunological  responses  have 
been studied so far. Both in horses and cats, CD4+ T cells dominate the 
perivascular  cuffs,  whereas  CD8+  T  cells  are  more  common  in  the 
parenchymal tissues, at least in horses (Bilzer et al., 1995; Lundgren et al., 
1995a). Overall, CD8+ T cells are less abundant than CD4+ T cells in the 
brain of BDV-infected cats (Berg et al., 1999b). BDV infection in cats causes 
an increase in the peripheral CD8+ T cells. This cell population can be 
divided into two subpopulations, CD8+low and CD8+high, based on the 
expression of the  -chain, and the CD8+low T cells dominate in the brain 
(Berg et al., 1999b). The exact difference between these two subpopulations 
is not entirely known, but it is thought that CD8+low T cells have similar 
functions to NK cells (Shimojima et al., 2004; Berg et al., 1999b). Plasma 
cells are found in the brain parenchyma, next to infected neurons in cats 
(Lundgren et al., 1995a), probably facilitating virus clearance. 
Immune Evasion Mechanisms of BDV 
To be able to establish a persistent infection, BDV needs to circumvent the 
host immune response. Several viruses have evolved type I IFN inhibiting 
properties, since these cytokines are key players in the innate host immune 
defense (Garcia-Sastre & Biron, 2006). BDV has also developed several ways 
to inhibit the expression of type I IFNs. 
When  BDV  replicates,  the  triphosphate  group  is  replaced  by  a 
monophosphate at the 5’-end of the genomic RNA (Schneider et al., 2005). 
Thereby, BDV, as well as ABV, avoids recognition by retinoid inducible 
gene I (RIG-I), which is an important cytosolic viral sensor and inducer of 
type I IFN gene expression (Reuter et al., 2010; Habjan et al., 2008). These 
findings  were  observed  when  genomic  RNA  was  transfected  into  cells. 
However, it is not known to what extent genomic RNA within the RNP 
is exposed to RIG-I in natural infections. BDV enters the cell by receptor-
mediated endocytosis as an intact viral particle, and is released as RNPs from   29 
the  early  endosome  into  the  cytoplasm,  followed  by  transport  to  the 
replication site inside the nucleus (Clemente & de la Torre, 2009; Gonzalez-
Dunia et al., 1998). Between cells inside the CNS and in cell culture, BDV 
spreads as RNPs (Clemente & de la Torre, 2007; Gosztonyi et al., 1993). 
Hence,  most  likely  other  cellular  receptors  sensing  viral  components  are 
important for the recognition of BDV, such as Toll-like receptors (TLRs) 3 
or 7/8 inside the endosomes, which recognize double-stranded and single-
stranded RNA respectively, or yet unknown viral sensors (Baum & Garcia-
Sastre, 2010). 
Thus,  to  evade  the  host  immune  response  and  establish  a  persistent 
infection, BDV has evolved other IFN-inhibiting strategies as well. BDV P 
interferes with the IFN-  mRNA expression by acting as a decoy substrate 
for  phosphorylation  by  TBK-1  (Unterstab  et  al.,  2005),  a  cellular  kinase 
activating transcription factors that enhance type I IFN expression. 
BDV  X  also  inhibits  the  type  I  IFN  system,  by  an  as  yet  unknown 
mechanism (Figure 7). Furthermore, there seems to be strain variation in the 
efficiency  of  inhibition.  Other  members  of  Mononegavirales  have  non-
structural  proteins  like  X,  with  similar  IFN-inhibiting  properties,  for 
example VP35 of Ebola virus (Basler & Amarasinghe, 2009) and V protein 
of paramyxoviruses (Goodbourn & Randall, 2009). 
One cellular defense mechanism upon type I IFN signal transduction is 
apoptosis induction (Chawla-Sarkar et al., 2003). Therefore, it is important 
to circumvent apoptosis to establish persistent infection. Certain persistently 
BDV-infected cell lines are resistant to apoptosis (Figure 2), and it is the X 
protein that is responsible for this resistance (Poenisch et al., 2009). The 
exact mechanisms by which X interferes with apoptotic pathways are not 
known. 
BDV has also developed mechanisms to evade the effects of IFN- , a key 
player within the adaptive immune response to viral infections, facilitating 
viral clearance by non-cytolytic mechanisms (Chesler & Reiss, 2002). One 
such antiviral effect of IFN-  is induction of inducible nitric oxide synthase 
(iNOS), which results in the production of free oxygen radicals, harmful to 
viruses. In rat astrocytes, BDV P inhibits the expression of iNOS (Peng et 
al., 2007), thereby overcoming this antiviral host response.   30 
 
Figure 7. BDV X induced type I IFN inhibition in A549 cells. Cells were co-transfected with 
an ISRE reporter plasmid and respective BDV X in a flag-tagged vector (1 µg). Twenty-four 
h post-transfection, type I IFN expression was induced by Sendai virus for 24 h, followed by 
luminescence reading of the luciferase activity. The luciferase activity was normalized to the 
positive control, consisting of empty flag-tagged vector. The asterisks indicate statistically 
significant differences, where ** is p<0.01, and *** p<0.001.  
Protein-Protein Interactions 
The  proteins  of  BDV  interact  with  each  other,  and  with  the  genomic 
RNA, to form the RNP and the virion, as previously discussed. BDV N 
interacts with P (Berg et al., 1998b; Schwemmle et al., 1998), which in turn 
interacts with L and X (Schneider, 2005; Schwemmle et al., 1998), as well as 
with  M  (Chase  et  al.,  2007).  Besides  these  interactions,  BDV  proteins 
interact with several host cellular proteins (Planz et al., 2009), with potential 
to  interfere  with  important  cellular  signaling  cascades  in  favor  of  viral 
persistence (Figure 8). 
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Figure 8. Map of interactions within BDV, between BDV and host cellular proteins, and the 
biological impact of these interactions. BDV proteins, and viral RNA (vRNA) are marked in 
red, whereas cellular proteins are in green. Phosphorylated BDV P (i) down-regulates the 
activity of the viral polymerase (BDV L; connector marked in red), (ii) acts as decoy substrate 
for TBK-1 and PKC  phosphorylation (purple connector), and (iii) competes with p53 for 
the same binding site of HMGB1 (yellow connector). The other interactions are described in 
the text. 
BDV N and P interact with the Cdc2-Cyclin B1 complex (Planz et al., 
2003), which is a crucial part of the cell cycle (Castedo et al., 2002). In the 
G2 phase of the cell cycle, the Cdc2-Cyclin B1 complex is acted on by a 
series  of  phosphorylations  and  de-phosphorylations,  resulting  in  nuclear 
translocation, which is important for the cells to enter the M phase (Castedo 
et  al.,  2002).  BDV  N  interacts  with  both  phosphorylated  and  non-
phosphorylated Cdc2, as well as with Cyclin B1, whereas BDV P interacts 
only with non-phosphorylated Cdc2 (Planz et al., 2003). Cells transfected 
with BDV N, had a reduced proliferation rate, indicating an interference of 
the G2 to M phase transition. This effect was also seen in BDV-infected 
cells, but not in cells transfected with BDV P. Thus, BDV interferes with 
cell proliferation to enable a persistent infection. 
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As previously discussed, BDV P interacts with TBK-1, and competitively 
interferes with the phosphorylation of endogenous substrates, resulting in 
decreased  type  I  IFN-expression  (Unterstab  et  al.,  2005).  Similar 
interference occurs in PKC  phosphorylation, where BDV P also acts as a 
decoy substrate, affecting neuronal plasticity (Prat et al., 2009). BDV P is 
also suggested to interfere with the normal transport of  -aminobutyric acid 
receptors (GABA-R) to the cell membrane, by interacting with GABA-R 
associated  protein  (GABARAP)  (Figure  9;  Peng  et  al.,  2008).  This 
interference could be responsible for causing some of the behavioral changes 
seen in BDV-infection, since decreased transport of GABA-R to the cell 
membrane  causes  anxiety  and  other  behavioral  changes  (Crestani  et  al., 
1999). Transgenic mice expressing BDV P have neurological signs similar to 
BDV-infection  (Kamitani  et  al.,  2003),  implicating  direct  disease-causing 
actions of P, possibly by interfering with the GABAergic neurotransmission. 
 
Figure 9. Interaction between BDV P (A) or N (B), and GABARAP in BDV-infected rat 
astrocytes. To visualize protein-protein interactions, in situ PLA was performed. Red staining 
indicates BDV-GABARAP interactions, and blue staining is the nuclei. Photos: Karl-Johan 
Leuchowius & Jonas J. Wensman.  
BDV  P  also  interacts  with  a  nuclear  protein,  called  high-mobility  group 
box-1 (HMGB1) (Kamitani et al., 2001). HMGB1 is involved in several 
cellular  functions,  such  as  transcriptional  regulation  (Ueda  &  Yoshida, 
2010),  DNA  repair  (Liu  et  al.,  2010),  cell  migration  (Rauvala  & 
Rouhiainen, 2010) and neurite outgrowth (Rauvala et al., 2000). In BDV-
infected  cells  and  in  cells  treated  with  BDV  P,  neurite  outgrowth  is 
impaired,  most  likely  because  of  decreased  secretion  of  HMGB1,  as  the 
result of binding with BDV P (Kamitani et al., 2001). 
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Figure 10. BDV P interferes with the functions of HMGB1. In the nucleus, BDV P out-
competes the binding of p53 to the A-box of HMGB1, thereby inhibiting the p53-mediated 
transcription, which can lead to apoptosis. Upon infection or cell damage, HMGB1 can be 
released, and bind to the cellular surface receptors TLR4 and RAGE, in turn inducing a pro-
inflammatory  response.  BDV  P  reduces  the  release  of  HMGB1,  and  hence  its  pro-
inflammatory actions. 
Upon infection or tissue damage, HMGB1 can be released and act as an 
alarmin, by binding to receptors at the cellular surface (TLR4 and RAGE), 
inducing a pro-inflammatory response (Yang et al., 2010). In BDV-infected 
cells,  RAGE  mRNA  expression  is  decreased  compared  to  non-infected 
cells,  further  strengthening  the  data  on  interference  of  normal  HMGB1 
function  by  BDV  P  (Kamitani  et  al.,  2001).  Moreover,  BDV  P  out-
competes the binding between HMGB1 and p53, resulting in impaired p53-
mediated  transcription  (Figure  10;  Zhang  et  al.,  2003).  This  interference 
could be another way for BDV to avoid apoptosis, since p53 is known to 
induce apoptosis of infected cells (Barber, 2001). Thus, BDV P interferes 
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with several antiviral, and other, actions of HMGB1 by binding to its p53-
binding site, and reducing its release from the cell. 
Epidemiology of Bornavirus Infections 
For a long time, BD was considered as a disease of horses and sheep in 
endemic  regions  of  Germany,  Switzerland,  Lichtenstein,  and  Austria 
(Ludwig & Bode, 2000). However, in the 1990’s several reports of cases 
outside  these  endemic  regions,  as  well  as  in  a  broader  host  range,  were 
published. These findings were preceded by the demonstration of BDV-
specific antibodies, antigens and RNA in humans from 1985 and onwards 
(Bode & Ludwig, 2003; Carbone, 2001; Ludwig & Bode, 2000; Rott et al., 
1985), which led to an increasing interest in BDV research. This section will 
focus on the epidemiology of BDV-infection in animals. 
Horses with BD have been shown to shed infectious viruses in nasal and 
lacrimal fluids (Richt et al., 2000). In addition, sub-clinically infected horses 
and sheep that are sero-positive can be PCR-positive in these body fluids, as 
well as in saliva (Vahlenkamp et al., 2002; Richt et al., 1993), indicating a 
potential  shedding  of  virus.  Hence,  BDV  could  spread  between  animals 
either by direct or indirect contact. However, this mode of spread is likely 
not the most important, because only sporadic cases are shown in the same 
stable  of  horses  (Richt  et  al.,  2000;  Ludwig  &  Kao,  1988).  Similarly, 
staggering disease in cats is mostly seen in only one cat in households with 
several  cats  (Berg  et  al.,  1998a).  Contradictory  data  concerning  vertical 
transmission of BDV in horses exist (Hagiwara et al., 2000; Richt et al., 
2000). 
In  horses  and  sheep,  cases  of  BD  are  observed  in  a  seasonal  pattern, 
where most cases are presented in late spring to early summer (Dürrwald et 
al.,  2006;  Richt  et  al.,  2000;  Dürrwald  &  Ludwig,  1997;  Ludwig  et  al., 
1985;  Schmidt,  1912).  A  similar  seasonal  distribution  is  also  seen  in  cats 
(Lundgren, 1992). Annual differences in disease incidence are also present in 
these species (Wensman et al., 2008; Dürrwald et al., 2006; Ludwig et al., 
1985). Together with the historically restricted endemic regions in BD of 
horses and sheep (Ludwig & Bode, 2000), as well as of cats (Wensman, 
2008;  Lundgren,  1992;  Kronevi  et  al.,  1974)  (Figure  11),  natural  BDV 
reservoirs have been discussed (Dürrwald et al., 2006; Staeheli et al., 2000; 
Lundgren, 1995).   35 
 
 
Figure  11.  Map  of  Sweden  showing 
regions  where  the  clinical  diagnosis 
“staggering  disease”  have  been  made 
during  the  years  1998-2008,  based  on 
data  from  the  Agria  Animal  Insurance 
Company. The size of the encircled areas 
is  approximately  proportional  to  the 
number  of  cases  reported.  In  total,  92 
cases  were  reported,  with  65%  coming 
from  the  previously  reported  endemic 
region (1, Areas around Lake Mälaren). 
In  regions  previously  considered  free 
from  disease,  cases  have  also  been 
reported,  like  the  west  coast  (3)  and 
southern parts (5) of Sweden. Numbers 
7-12  represent  individual  cases,  spread 
over  the  country.  From  Wensman 
(2008). 
 
 
Wildlife Reservoirs 
Because of the persistent infection in experimentally infected rats and mice, 
resulting in either mild behavioral changes or in sub-clinical infection only 
(Ludwig et al., 1985), rodents have been proposed as a natural reservoir of 
BD (Dürrwald et al., 2006; Staeheli et al., 2000). Experimentally infected 
rodents can transmit BDV both by close contact (horizontal transmission) 
(Sauder & Staeheli, 2003) and from mother to fetus (vertical transmission) 
(Okamoto et al., 2003). Hence, a persistent infection could be maintained 
within a rodent population in nature, and spread BDV to domestic animals 
through  shedding  of  infectious  viruses.  In  cats,  it  is  mainly  those  with 
outdoor access, hunting rodents, that are at higher risk of BDV-infection 
(Berg et al., 1998a).  
Interestingly, recent studies in Finland have shown the presence of BDV-
specific antibodies in wild rodents, namely different kind of voles (Kinnunen 
et  al.,  2007).  Upon  experimental  BDV-infection,  bank  voles  did  not 
develop  pathological  alterations  in  the  CNS,  despite  the  fact  that  BDV-
RNA and BDV-antigen were found both in the CNS and in peripheral 
neural ganglia (Kinnunen et al., 2011). Most of the voles did not show any 
clinical  signs,  but  some  of  them  presented  with  hyperactivity  or  other   36 
neurological  signs.  BDV-RNA  was  detected  in  the  feces  and  urine, 
indicating  potential  shedding  of  infectious  virus.  Thus,  voles  could  be  a 
wildlife  reservoir,  and  an  infection  within  the  population  maintained 
persistence by viral shedding in feces and urine. At least in rats, BDV is 
transmitted only upon close contact for at least 24 hours, most likely by 
infectious viruses shed in urine (Sauder & Staeheli, 2003). Thereby, if BDV 
is transmitted to domestic animals, such as horses and sheep, when infected 
rodents are contaminating their feed, this contamination probably needs to 
be intensive and repeated. However, in cats the transmission most likely 
takes place when infected rodents, such as voles, are preyed upon. Whether 
the  behavioral  changes  that  sometimes  can  be  seen  in  infected  voles 
(Kinnunen et al., 2011) affect the possibility for these animals to be a prey is 
not  known.  However,  it  is  known  that  the  parasite  Toxoplasma  gondii 
(Apicomplexa) can change the behavior of the intermediate host (rodents) 
to become an easier prey for the main host, the cat (Webster, 2007). 
Another proposed reservoir is wild birds. So far, the only finding of BDV 
reported  from  wild  birds  comes  from  Sweden,  where  BDV-RNA  was 
detected in feces of mallards and jackdaws (Berg et al., 2001). Even though 
the BDV sequences isolated from these birds were similar to other known 
reference strains and isolates, some differences were seen (Wensman et al., 
2008; Berg et al., 2001). Recent findings of ABV have raised the question of 
whether the isolates found in wild birds are more closely related to the new 
ABV than previously known. Interestingly, experimental ABV infection in 
mallards does not result in any clinical signs or pathological lesions (Hoppes 
et al., 2010), although feces from infected animals is intermittently PCR-
positive,  and  antibodies  can  be  found.  Furthermore,  ABV  can  be 
transmitted by the fecal-oral route to mallards, which accidentally happened 
in  non-infected  control  mallards  when  they  were  kept  together  with  a 
group  of  sub-clinically  infected  cockatiels  (Hoppes  et  al.,  2010).  Most 
recently,  Canada  geese  and  trumpeter  swans  with  non-suppurative  CNS 
inflammation  were  found  to  be  ABV-positive,  carrying  a  new  distinct 
genotype of ABV (Delnatte et al., 2011).  
Mallards,  as  well  as  other  migratory  birds,  are  well-known  carriers  of 
other viruses, such as influenza virus, West Nile virus and Newcastle disease 
virus. The migration route of mallards in Northern Europe goes from parts 
of Germany, where BD is considered to be endemic, to Northern Siberia, 
passing  over  Sweden.  Hence,  wild  birds  such  as  mallards,  could  be 
important for transporting BDV from endemic regions to previously non-
endemic areas.   37 
Ticks  have  also  been  considered  to  be  a  possible  reservoir,  since 
approximately the same regions endemic for BDV are endemic for tick-
borne encephalitis virus. However, ticks are probably only mechanical or 
accidental  vectors,  because  BDV  does  not  seem  to  replicate  in  ticks 
(Schindler, 2004). 
In BDV-endemic regions of Central Europe, bi-colored white-toothed 
shrews have been found to carry BDV (Hilbe et al., 2006). These animals do 
not show any obvious clinical signs. They harbor BDV in many different 
tissues, indicating a persistent infection as in rodents (Puorger et al., 2010; 
Hilbe  et  al.,  2006).  Thereby,  this  insectivore  could  be  another  potential 
reservoir  of  BDV  in  certain  parts  of  Europe.  However,  neither  this 
particular shrew nor any of its closest relatives have their habitat in Sweden. 
Other  species  have  also  been  found  to  carry  BDV  or  BDV-specific 
antibodies without showing obvious clinical signs, or with unknown clinical 
status. In Japan, macaques (12%) and raccoons (2%) have been shown to be 
seropositive (Hagiwara et al., 2009; Hagiwara et al., 2008). Furthermore, in 
a few animals of both species BDV-RNA could be found. In France, BDV-
RNA has been found in four brain samples from red foxes of unknown 
clinical status (Dauphin et al., 2001). Whether these findings describe sub-
clinical  persistent  infections  or  animals  with  clinical  disease,  and  the 
potential for these species as reservoirs for BDV, remains unclear. 
If there is a wildlife reservoir for BDV, there is obviously not just one, 
but most likely there are various reservoirs in different parts of the world. 
Based  on  the  estimated  incubation  times,  from  several  weeks  in  sheep 
(Ludwig & Kao, 1988; Heinig, 1969) up to six months in horses (Mayr & 
Danner, 1974), and the reported seasonal distribution of BD cases, natural 
infection can actually occur all year around in these species. The incubation 
time in cats is not known, but upon experimental intra-cerebral infection it 
takes three weeks up to 2.5 months for clinical signs to develop (Lundgren 
et  al.,  1997).  If  these  experimental  data  reflect  the  true  incubation  time, 
natural infection should occur mainly from September to April. The mode 
of  spread  of  BDV  therefore  most  likely  varies  between  different 
domesticated species, depending on their feeding preferences and how they 
are housed. 
Diagnostics of BDV-Infection 
Ante-Mortem Diagnostics 
Due to the nature of any persistent infection within the CNS, it is difficult 
to find specific BDV-markers, such as antigens, antibodies or RNA, in a   38 
living  animal  with  suspected  disease.  BD  is  therefore  mainly  a  tentative 
diagnosis  in  different  animals,  made  by  ruling  out  other  possible 
explanations  for  the  clinical  signs.  Even  though  the  clinical  signs  are 
characteristic, they are not specific for BDV-infection. 
Serology is potentially an aid for the clinician, but in horses with BD the 
antibodies are not always found in serum, and clinically healthy horses can 
carry  antibodies  (Richt  et  al.,  2000;  Ludwig  et  al.,  1985).  Similar 
observations have been made in cats. Naturally infected cats developed low 
or no titers of antibodies, whereas experimentally infected cats developed 
high titers (Johansson et al., 2002). Other studies have shown antibodies in 
clinically healthy cats (Helps et al., 2001; Ouchi et al., 2001). Depending on 
the sensitivity and specificity of the assay used, the sero-prevalence differs 
even  in  the  same  geographical  region.  The  indirect  immunofluorescence 
assay (IFA) is used most commonly (Herzog & Rott, 1980; Ludwig et al., 
1973).  The  sero-prevalence  of  BDV  in  endemic  regions  is  around  20% 
using this method (Richt et al., 2000), and lower in non-endemic areas. In 
the  past  decade,  enzyme-linked  immunosorbent  assays  (ELISA)  detecting 
antigens,  antibodies  or  circulating  immune  complexes  (CIC)  have  been 
developed, which seem to have higher sensitivity (Bode et al., 2001). The 
sero-prevalence  of  BDV  has  been  reported  as  high  as  60%  in  endemic 
regions  using  these  assays  (Ludwig,  2008;  Ludwig  &  Bode,  2000).  This 
could indicate that there is no need for reservoirs for the viral spread (Bode, 
2008).  There  seems  to  be  high  cross-reactivity  between  different  viral 
strains, as IFA using cells infected with an equine BDV strain detected high 
titers  of  antibodies  in  psittacine  birds  infected  with  ABV  (Herzog  et  al., 
2010),  indicating  a  broad  detection  range  using  this  classical  method  for 
antibody detection. 
Antibody  detection  in  cerebrospinal  fluid  (CSF)  is  considered  to  be 
highly specific for BDV-infection, because antibodies have not been found 
in healthy horses (Richt et al., 2000; Ludwig & Thein, 1977). 
Molecular biological assays for detection of viral nucleic acids (RNA) in 
clinical  samples  have  been  widely  used,  especially  for  blood  samples 
(Vahlenkamp  et  al.,  2002;  Vahlenkamp  et  al.,  2000;  Berg  et  al.,  1999a; 
Hagiwara et al., 1997; Nakamura et al., 1996; Nakamura et al., 1995). Even 
though  viral  RNA  has  been  found  in  PBMCs  and  in  body  fluids  from 
horses and sheep with clinical disease (Vahlenkamp et al., 2000; Richt et al., 
1993), this is only for a limited number of cases. Due to the limitations of 
RT-PCR,  only  those  variants  of  BDV  with  sequence  similarities  to  the 
primers of the assay will be detected. BDV is considered to have a high 
degree of genetic conservation, but a more divergent strain has been found   39 
(Nowotny et al., 2000). The recent findings of the even more divergent 
ABV (Honkavuori et al., 2008; Kistler et al., 2008), could indicate higher 
divergence  than  previously  considered.  Hence,  the  different  RT-PCR 
assays developed so far could fail to detect viral RNA in several cases, due to 
sequence dissimilarities. 
Concerns have been raised about the high risk of contamination when 
using sensitive assays such as RT-PCR and nested RT-PCR (Dürrwald et 
al., 2006). This contamination risk is not unique for BDV, and holds true 
for all RT-PCR and nested RT-PCR assays, and can be reduced by the use 
of real-time RT-PCR (rRT-PCR) without losing sensitivity (Belák et al., 
2009; Schindler et al., 2007; Belák & Thorén, 2001). 
 
Figure 12. Perivascular cuff consisting of mononuclear cells is one characteristic pathological 
lesion in BDV-infection. The section comes from a cat suffering from feline BD. Apart from 
perivascular  cuffs,  lymphocytic  infiltration  is  also  seen  in  the  brain  parenchyma. 
Hematoxylin-Eosin stain. Magnification: lens x20. Photo: Gete Hestvik.   
Post-Mortem Diagnostics 
BDV-infection  is  confirmed  at  necropsy,  based  on  the  pathognomonic 
intra-nuclear inclusion bodies in neurons, named after Joest and Degen who 
discovered  them  (Joest  &  Degen,  1911),  and/or  the  presence  of  a  non-  40 
purulent inflammation of typical regions of the CNS (Figure 12), olfactory 
bulb,  gray  matter  of  the  brain  stem,  basal  ganglia  and  hippocampus 
(Lundgren, 1992; Gosztonyi & Ludwig, 1984; Joest & Degen, 1911). The 
presence of BDV-antigen and/or -RNA in situ further confirms the correct 
diagnosis. However, in some species, such as cats, the viral load seems to be 
lower compared to horses, since the staining by IHC is commonly weaker 
(Lundgren et al., 1995a). 
Antigen detection (Ludwig & Becht, 1977) and/or nucleic acid detection 
(Zimmermann  et  al.,  1994b)  in  brain  homogenates  further  confirm  the 
infection. 
Humans and BDV 
The intriguing results of experimental infection in the lower primate tree 
shrew  (Sprankel  et  al.,  1978),  resulting  in  different  behavioral  changes, 
which were also seen later in rats infected as new-borns (reviewed in Briese 
et al., 1999), led to the question whether BDV could be involved in human 
disease.  The  first  serological  evidence  of  human  BDV-infection  was 
discovered in patients with affective disorders, whereas the control subjects 
without signs or history of these disorders were all negative (Rott et al., 
1985).  
This finding led to worldwide efforts to study similar and other patient 
groups,  using  serological  techniques,  staining  for  antigen  and  RNA  in 
tissues, and molecular methods (Bode & Ludwig, 2003; Carbone, 2001). By 
these  methods,  BDV  was  detected  in  brain  tissues  of  humans  with 
hippocampal sclerosis (Czygan et al., 1999; de la Torre et al., 1996). The first 
human BDV-variant was isolated in cell cultures and in laboratory animals 
from  brain  tissue  of  a  patient  with  schizophrenia,  and  sequence  analysis 
showed genetic similarities to other isolated BDV-strains (Nakamura et al., 
2000). BDV has also been considered a cause of viral encephalitis (Li et al., 
2009). 
Because of the close genetic relationship of most BDV-isolates in humans 
as well as in animals, false positive results due to laboratory contamination 
have  been  discussed  (Dürrwald  et  al.,  2007).  Recent  findings  show  that 
BDV-like elements have been incorporated into the genome of humans, 
and other mammals (Belyi et al., 2010; Horie et al., 2010). Whether these 
data support the reports of BDV-infection in humans, or could influence 
results  based  on  molecular  biological  detection  methods,  is  an  open 
question.   41 
Treatment and Prophylaxis 
During the 19
th and early 20
th century, several herbal and medical treatments 
were  employed  on  horses  with  BD,  but  none  of  them  seemed  to  work 
(Zwick, 1939; Nicolau & Galloway, 1928; Schmidt, 1912). More recently, 
anti-viral drugs have been investigated for their potential inhibition of viral 
replication in infected cell cultures, and in experimentally infected animals. 
Ribavirin has been promising in cell cultures (Jordan et al., 1999; Mizutani 
et al., 1998) and in experimentally infected animals (Lee et al., 2008; Solbrig 
et al., 2002), partly by facilitating the non-cytolytic viral clearance of the 
host immune response (Solbrig et al., 2002). However, its use in naturally 
infected animals remains unknown. In addition to in vitro studies, another 
drug,  amantadine,  has  been  used  for  treatment  of  natural  infection  in 
animals and humans (Dieckhöfer, 2008; Dietrich & Bode, 2008; Ohlmeier 
et al., 2008; Dieckhöfer et al., 2004; Bode et al., 1997), though its antiviral 
effects on BDV in cell cultures have been questioned (Cubitt & de la Torre, 
1997; Hallensleben et al., 1997). 
Cats with feline BD have been commonly treated with corticosteroids, 
to reduce the inflammatory response, and the clinical signs this response lead 
to. This treatment seems to be beneficial when used in the early stage of 
disease  (Wensman  et  al.,  2011;  Berg,  1999),  though  the  use  of 
immunosuppressive treatment could lead to increased virus replication. 
Early work by Zwick and his coworkers showed that it was possible to 
immunize horses, preventing clinical disease upon viral challenge (Zwick et 
al.,  1928).  Therefore,  vaccination  occurred  in  Germany  from  the  1920’s 
onwards,  though  it  was  recommended  only  in  endemic  regions (Heinig, 
1969). In the former Federal Republic of Germany (West Germany), the 
efficacy of the vaccine was questioned, and vaccinations ended in the late 
1970’s  (Dürrwald  et  al.,  2006).  The  vaccinations  in  the  former  German 
Democratic Republic (East Germany) did not come to an end until the 
reunification of Germany. The spread of BDV due to vaccination with live 
vaccine  strains  has  been  suspected  (Ludwig  &  Bode,  2000),  though 
according to molecular epidemiological data this spread seems to have been 
limited (Dürrwald et al., 2006). Today there is no medical prophylaxis in use 
to prevent BDV infection, though isolation of sick animals and hygienic 
safety measures can reduce the spread of disease (Ludwig & Bode, 2000).   42 
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Aims of the Thesis 
The overall aims of this thesis were to improve current detection methods, 
and  to  increase  knowledge  about  BDV-host  interactions,  especially  in 
naturally infected animals. 
 
The specific aims were to 
 
   Develop  novel  methods  for  improved  detection  of  BDV  infection 
markers (RNA, antigen, and antibodies; Papers I, II & III); 
   Apply  and  evaluate  these  methods  in  cats  with  BD  to  improve  the 
current ante-mortem diagnostics (Paper II); 
   Study BDV-host protein-protein interactions in infected animals (Paper 
III); 
   Study the host immune response in feline BD (Paper IV) and its possible 
implication for development of clinical signs (Paper II). 
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Materials and Methods 
This section will briefly discuss and comment on the materials and methods 
used in the studies of this thesis. More detailed descriptions are provided 
within each individual paper. 
Sampling 
An essential part of virus detection, as well as gene expression analyses, is 
sampling,  and  sample  handling.  Brain  tissue  samples  from  cats  with  or 
without signs of BDV-infection were collected at necropsy (Papers I, II & 
IV). For all cats studied in Paper II and for some of the cats used in Paper 
IV, necropsy was performed in close connection with euthanasia. However, 
in  Paper  I  and  in  the  majority  of  the  cases  in  Paper  IV,  the  time  from 
euthanasia to necropsy and sampling was probably around 24 h. During this 
time, the carcasses had been stored at c. +4°C. In most cases, tissue samples 
were not snap-frozen, but just put immediately into a deep freezer (c. 
70°C). Similar handling is likely for samples taken at the clinics (Paper II).  
Some samples had been exposed to repeated thawing and freezing cycles. 
These handling procedures probably negatively influence the outcome of 
both virus detection and gene expression analyses. As discussed below, for 
gene expression analyses, this can be overcome by using reference genes 
when normalizing the data. 
RNA-Extraction 
RNA is known to be sensitive to degradation by ribonucleases (RNase), 
which are present everywhere. It is therefore important to reduce potential 
exposure to RNase, for example by using RNase-free reagents and plastics,   46 
and to reduce the possibility for RNase to be active, for example by keeping 
the RNA at a low temperature for as long as possible. 
In  the  studies  presented  in  this  thesis,  total  RNA  was  extracted  by  a 
phenol and guanidine isothiocyanate solution (TRIzol or QIAzol reagent, 
Invitrogen or Qiagen, respectively), in combination with the addition of 
chloroform,  according  to  the  manufacturer’s  recommendations.  A 
combination  of  this  technique  and  on-column  RNA  isolation  (Qiagen), 
sometimes with a DNase treatment step, was used to improve the quality of 
the RNA (Papers II & IV). 
Regardless of extraction method, a most crucial step is homogenization 
of tissues. For brain tissues, homogenization is best performed in TRIzol or 
QIAzol. As BDV causes a persistent infection within the CNS of cats, this 
virus is only present at low levels. The presence of the virus is also brain 
region specific. Even if the correct brain region is chosen, there could be 
differences in viral load within this region. Only a small piece of brain is 
used for each RNA-extraction (approx. 0.5 cm
3), hence, there could be 
false negatives because of picking the “wrong” piece. 
If the RNA is eluted in too high a volume, the viral RNA could be 
diluted  below  the  limit  of  detection.  This  dilution  effect  could  be  the 
explanation  for  why  manually  extracted  RNA  from  blood  samples  was 
positive  (Paper  II)  while  robot  extracted  RNA  was  negative  (data  not 
shown).  
cDNA-Synthesis 
Synthesis  of  cDNA  or  reverse  transcription  (RT)  can  be  performed  in 
several ways. In Paper I, cDNA-synthesis was included as the initial step in a 
one-step rRT-PCR using the same enzyme and primers as the following 
PCR. This approach decreases the time of handling, and the possibility for 
contamination due to multiple opening of tubes and during pipetting.  
Synthesis of cDNA for BDV detection was performed either in a one-
step rRT-PCR or as a separate step (two-step rRT-PCR; Papers II & IV). 
In  the  two-step  approach,  gene-specific  primers  were  used  (Berg  et  al., 
2001),  together  with  Superscript  III  (Invitrogen),  as  this  approach  was 
shown to have higher sensitivity, compared to random hexamers as cDNA-
primers or the use of commercial RT-primers (Qiagen). However, there is 
a risk of false negative results when using gene-specific primers for cDNA-
synthesis, as these primers could miss more divergent strains. 
 Oligo(dT)-primers specific for the poly-A tail of mRNA were used for 
gene  expression  analyses  (Paper  IV).  As  some  genes  are  intron-less,  like   47 
IFN-  and - , it is important to carry out a –RT reaction (without RT 
enzyme) as a control for genomic DNA contamination. This approach is 
also important when primer and probe design are not performed to cover an 
intron-exon  junction,  thereby  decreasing  the  possibility  of  contaminating 
genomic DNA contributing to the amplification of a PCR product. In my 
experience, this technical control is crucial for all gene expression analyses, 
at least in an initial optimization of (r)RT-PCR assays. 
Real-Time RT-PCR 
Real-time  or  quantitative  RT-PCR  has  revolutionized  gene  expression 
analysis and molecular diagnostics. This method is easy to automate by the 
use of pipetting robots, thereby increasing speed and decreasing the need for 
laboratory  personnel.  Furthermore,  the  possibility  for  absolute  or  relative 
quantification of gene expression has made rRT-PCR the gold standard for 
confirmation of global gene expression analysis (microarray data). 
Several different chemistries are available for rRT-PCR. In the studies 
presented in Papers I, II & IV, the TaqMan-probe chemistry was used. The 
TaqMan-probe  is  an  oligonucleotide,  complementary  to  the  target 
sequence,  labeled  with  a  reporter  dye  and  a  quencher.  In  Paper  I  6-
carboxyfluorescein (FAM) and 6-carboxy-X-rhodamine (ROX) were used 
as reporter dyes, and in Papers II & IV FAM was used. In all TaqMan-based 
assays (Papers I, II & IV), black hole quencher (BHQ) was used. BHQ has 
the  advantage  of  emitting  heat  instead  of  light  upon  excitation,  thereby 
decreasing possible background signals. 
TaqMan-based  assays  are  gene-specific,  while  SYBR-green  is  an 
intercalating dye, binding non-specifically to any double-stranded nucleic 
acid  (RNA/DNA).  The  latter  chemistry  was  used  for  the  rRT-PCR  of 
reference genes (Paper IV). 
Primer and Probe Design 
The  design  of  primers  and  probes  is  an  important  step  for  every  PCR, 
because  primers  and  probes  determine  the  specificity  of  the  assay.  This 
design can be done using different software, though manual design is still 
valid.  If  multiple  variants  of  the  target  sequence  are  aligned,  the  use  of 
software will facilitate the design, especially if degenerate sites in the primers 
are allowed. 
If 5’-AT rich overhangs are added to the primers then the sensitivity of 
the rRT-PCR assay has been shown to increase (Afonina et al., 2007). The 
BDV P and L primers (Paper I), as well as the BDV N primers (Schindler et   48 
al., 2007), were modified in this way to see if this possibility was true also in 
these systems. For BDV P, the achieved fluorescence was higher, though 
CT-values remained similar, thereby giving a more secure signal in dubious 
samples. However, in the BDV L assay, this effect was not as obvious, and 
for BDV N the original primers were better than the modified ones. Most 
likely, 5’-AT rich overhangs are more important if the primers used are 
degenerate, as in the case of BDV P and L. When consensus primers are 
used, as in the case of BDV N, modifying the primers is not beneficial. 
Determination of Sensitivity 
The sensitivity of rRT-PCR is usually superior to that of conventional RT-
PCR,  and  is  c.  1-100  copies  of  the  targeted  gene  or  viral  genome  per 
reaction. This level of sensitivity is similar to that of nested RT-PCR, but 
with  the  advantage  of  not  handling  PCR-products  as  templates  for  the 
second round of PCR (Belák et al., 2009). 
However, analytical sensitivity (determination of the lowest virus level 
needed for detection) is just an approximation, because it is determined by 
calculating number of copies of a plasmid or in vitro translated RNA based 
on the DNA/RNA concentration and molecular weight of the nucleic acid. 
Then, a dilution series is made according to these calculations. Hence, there 
are several approximations, as well as possibilities for pipetting errors when 
determining the analytical sensitivity. 
The diagnostic sensitivity is determined by using a number of known 
infected  samples  (Belák  &  Thorén,  2001).  However,  this  determination 
relies on a second assay for detection of infection, which is difficult in BDV-
infection. In the studies of this thesis, typical clinical signs and characteristic 
pathological lesions have been used as a “gold standard” for BDV-infection 
(Papers I, II & IV). 
In situ PLA 
Until recently, studies of protein-protein interactions in situ in tissues or in 
genetically unmodified cells have been difficult. A novel and selective tool 
to  study  individual  proteins  or  protein-protein  interactions,  the  in  situ 
proximity ligation assay (PLA), was developed to meet this need (Söderberg 
et  al.,  2006),  and  is  now  available  commercially  (Duolink,  Olink 
Bioscience).  
In situ PLA was used for detection of BDV-proteins, as well as for BDV-
host  protein-protein  interactions  in  persistently  infected  cells  and  brain 
tissues  from  experimentally  and  naturally  infected  animals  (Paper  III).  At   49 
first,  fluorescently  labeled  detection  oligonucleotides  were  used  also  for 
tissue samples (Figure 13), but because of a high degree of auto-fluorescence 
in brain tissues the fluorescence was converted to chromogenic signals by 
DuoCISH (Dako). 
 
 
 
 
Figure  13.  BDV P in  situ  PLA of  brain 
tissue  from  an  experimentally  infected 
cat. BDV P is labeled red, glial fibrillary 
acidic  protein  (GFAP)  as  a  marker  for 
glial cells is labeled green, and cell nuclei 
are labeled blue. There is a high degree 
of  auto-fluorescence,  especially  in  the 
green  filter.  Photo:  Karl-Johan 
Leuchowius.
 
Antibody Selection 
For  all  antibody-dependent  methods,  antibody  selection  is  crucial.  In 
veterinary medicine there is usually a lack of reagents suitable for the species 
of interest, especially if several different species are to be studied. For the 
studies in Paper III, commercial antibodies for detection of different cellular 
proteins  were  purchased  (Abcam).  The  antibodies  were  chosen  for  their 
broad species recognition and for their proven usage in IHC and/or IFA. 
Initially, the antibodies were evaluated by IFA, where antibody titrations 
were performed. Then, the antibodies were used in the in situ PLA in cells, 
to detect potential BDV-host protein-protein interactions. For tissues, an 
initial antibody evaluation was performed by IHC, followed by in situ PLA. 
Gene Expression Analysis 
As  previously  discussed,  rRT-PCR  has  become  widely  used  for  gene 
expression  analysis  and  for  confirmation  of  microarray  data.  However, 
mRNA expression does not necessarily lead to translation into a protein. 
Therefore,  protein  expression  and  activity  analysis  is  further  needed,  in 
order to determine whether an increase or decrease in gene expression is 
biologically relevant. 
Moreover, for some genes that are constitutively expressed and/or key 
regulators,  a  small  increase  or  decrease  could  lead  to  a  high  biological 
impact.   50 
Reference Genes 
As the quality of tissues, and hence also the quality of the RNA, used in 
Paper IV was affected by sample handling, especially different time from 
euthanasia  to  necropsy,  sampling,  and  freezing  of  samples,  the  use  of 
reference  genes  was  essential.  The  RNA  quality  is  not  essential  in  gene 
expression  analysis  by  rRT-PCR,  because  the  PCR-products  are  usually 
relatively  short  (<250  bp),  thus  the  results  are  less  affected  by  RNA 
degradation (Nolan et al., 2006). However, the use of reference genes is 
needed to compensate for imperfect RNA quality. 
Moreover, it is most important to use more than one reference gene, 
especially when handling samples taken at necropsy (Nolan et al., 2006). It is 
also crucial to select the right reference genes for the tissue of interest, based 
on  the  stability  of  expression  (Vandesompele  et  al.,  2002).  In  Paper  IV, 
previously validated feline reference genes were used (Penning et al., 2007); 
however, brain tissue specific selection, based on expression stability, was 
performed.  Reference  genes,  where  genomic  DNA  was  substantially 
amplified, were avoided. 
Normalization of Data 
There  are  several  ways  to  normalize  rRT-PCR  data.  In  Paper  IV,  the 
individual CT-values of the gene of interest, as well as the reference genes, 
were  inverted,  in  order  to  interpret  the  obtained  data  more  easily 
(Jiwakanon et al., 2010). Lower CT-values mean higher gene expression, and 
vice versa. Without inverting the CT-values, an increase in gene expression 
is therefore seen as a lowered value, which renders the data more difficult to 
interpret. 
For normalization, the average of three reference genes was used for each 
individual sample, which should give the normalized data more validity. In 
previous feline gene expression analyses, mostly one reference gene has been 
used for normalization (Penning et al., 2007).  
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Results and Discussion 
Papers I, II & IV – Detection of BDV-Infection Markers in Cats 
The  safe  diagnosis  of  feline  BD  is  hampered  by  a  lack  of  fully  reliable 
diagnostic methods for the confirmation of BDV-infection in the live cats. 
For  the  clinician,  staggering  disease  or  feline  BD  is  therefore  a  tentative 
diagnosis  made  by  ruling  out  other  possible  explanations  for  the  clinical 
signs. Previous studies have detected BDV-RNA in different body fluids of 
infected  horses  and  sheep  (Vahlenkamp  et  al.,  2002;  Berg  et  al.,  1999a; 
Richt  et  al.,  1993),  suggesting  rRT-PCR  as  one  way  of  confirming 
infection. Serological methods have been widely used for a long time in 
several species (Bode et al., 2001; Lundgren & Ludwig, 1993; Herzog & 
Rott, 1980; Ludwig & Thein, 1977; Ludwig et al., 1973), though cats are 
thought to develop only low or non-detectable antibody titers upon natural 
BDV-infection  (Johansson  et  al.,  2002).  Moreover,  antibodies  have  been 
detected in healthy cats, and the prevalence in the normal cat population is 
unknown,  which  makes  it  even  more  difficult  to  interpret  serological 
results.  For  this  reason,  an  rRT-PCR  was  developed  (Paper  I),  and 
evaluated for its clinical diagnostic value (Papers II & IV). BDV-serology 
was established and evaluated, with special regard to antibody prevalence in 
a reference cat population (Paper II). 
Detection of BDV-RNA 
An rRT-PCR assay was developed for simultaneous detection of BDV P 
and L genes, either in a one-tube (duplex) or a two-tube (simplex) format 
(Paper I). Primers and probes for BDV P and L were designed by aligning 
several BDV-strains, including the most divergent strain known at that time, 
BDV No/98 (Pleschka et al., 2001; Nowotny et al., 2000), to have as broad 
an assay as possible. All reference strains of BDV (strains V, He/80, and   52 
No/98)  were  detected,  as  well  as  five  field  strains  from  brain  tissues  of 
naturally infected cats, and a feline isolate previously used in experimental 
infection  of  cats  (Lundgren  et  al.,  1997;  Lundgren  et  al.,  1995b).  As 
expected, non-BDV viruses used in the specificity test were not detected. 
The assays had high analytical sensitivity: down to 10 copies per reaction 
could be detected in the two-tube format of both targeted genes, and in the 
one-tube  format  of  BDV  P.  In  the  one-tube  format  of  BDV  L,  the 
analytical sensitivity was 10-fold decreased, so that approximately 100 copies 
per reaction were detected. This decrease could be due to primer-probe 
competition, often seen in multiplex PCR-assays. The BDV L primers had 
several degenerate sites. Therefore, there is not only a set of two primers in 
this assay, but a mixture of several variants of the different primers, which 
could further increase the possibility for competition. 
In the analysis of field strains, BDV L was detected in four out of five 
samples, but only at very low levels, whereas BDV P was easily detected in 
all  samples  (Paper  I).  Hence,  BDV  L  is  not  as  suitable  for  diagnostic 
purposes  as  BDV  P.  This  system  was  therefore  not  used  in  the  further 
studies (Papers II & IV). BDV N and P are the most abundant genes, based 
on the 3’ – 5’ decrease in molarity of gene transcripts common to all viruses 
of the order Mononegavirales. Therefore, an rRT-PCR for BDV N was also 
used (Schindler et al., 2007) to increase the likelihood of detection (Paper 
II). The BDV P rRT-PCR was modified to increase the sensitivity (Papers 
II & IV; Afonina et al., 2007). 
In the study presented in Paper II, cats fulfilling the clinical inclusion 
criteria (gait disturbances with or without behavioral changes) and having 
characteristic pathological lesions were sampled at the clinic and at necropsy 
for detection of BDV-RNA. In eleven of 19 cats (58%), BDV-RNA was 
detected  in  at  least  one  sample,  taken  both  at  the  clinic  (N=6),  and  at 
necropsy (N=6). In two cats, multiple samples, taken both at the clinic and 
at necropsy, were positive for BDV-RNA. Most commonly, BDV-RNA 
was detected in blood (N=5), and olfactory epithelium (N=4), but BDV-
RNA was not detected in nasal fluids, as has been found in horses and sheep 
(Vahlenkamp et al., 2002; Richt et al., 1993). As the majority of the positive 
blood samples (3 out of 5) came from cats showing mild neurological signs, 
rRT-PCR could be helpful for confirmation of the diagnosis in these cases. 
Not  all  cats  showing  characteristic  neurological  signs,  and  typical 
pathological lesions, of feline BD, were confirmed to be positive by rRT-
PCR (Papers II & IV). The explanations could be the low viral load in cats 
(Lundgren  et  al.,  1995a)  compared  to  for  example  horses,  where  BDV-
RNA most often can be easily detected by (r)RT-PCR (Dürrwald et al.,   53 
2006) and/or sequence dissimilarities. So far, no feline BDV isolate has been 
completely sequenced, and there are only a few partial sequences available. 
The difficulty of obtaining (longer) sequences from feline BDV isolates is 
probably due to the low viral load in cats and/or sequence dissimilarities, in 
combination with sampling procedure and sample handling. Thus, it is still 
not known whether some feline strains are more similar to ABV, or if ABV 
can infect cats, as the rRT-PCR used in these studies probably does not 
detect the more divergent ABVs. 
Detection of BDV-Specific Antibodies 
As  BDV-RNA  was  not  detected  in  all  cats  with  feline  BD,  serological 
investigation was also performed (Paper II). In this study, a classical method 
for antibody detection, IFA, was used. This method is routinely used at the 
National  Veterinary  Institute  (SVA)  in  Sweden,  though  not  yet  for 
detection of BDV-specific antibodies. 
BDV-specific antibodies were detected in serum samples from 13 of 16 
tested  cats  (81%).  In  the  studied  reference  population  at  highest  risk  for 
exposure of BDV, 16% were positive. This is a similar proportion to that of 
healthy horses in endemic areas of Germany, using the same method (Richt 
et al., 2000). The number of cats included in the study is limited (feline BD 
cases: N=16; high risk reference population: N=25), but if the results reflect 
the situation in a larger population of cats, the positive prediction value in 
endemic regions is 76%, and the corresponding negative prediction value is 
88%.  Three  cats  with  feline  BD  had  antibodies  in  their  CSF.  As  BDV-
specific antibodies are only detected in the CSF of horses with BD (Richt et 
al., 2000; Ludwig & Thein, 1977), the presence of antibodies in CSF is 
highly indicative of BDV-infection. 
In Paper II, all cats studied had typical clinical signs of feline BD, as well 
as  pathological  lesions  in  concordance  with  BDV-infection.  Feline  BD 
should be high on the list of differential diagnoses when a cat presents signs 
like ataxia, absent or decreased postural reactions and menace response, and 
behavioral changes, especially if the cat has outdoor access. Previously, feline 
BD was considered to be present in Sweden only in the areas around Lake 
Mälaren (Lundgren, 1992; Kronevi et al., 1974), but lately the disease has 
been diagnosed in other regions of Sweden as well (Figure 11; Wensman, 
2008). Serology would further confirm the clinical suspicion in these cases. 
However, the situation remains unclear for more questionable cases, as these 
probably have not fulfilled the inclusion criteria of this study. Whether it is 
more  common  for  cats  with  typical  signs  of  feline  BD  to  develop  an 
antibody response is not known, however, it seems unlikely. Further studies   54 
of  the  prevalence  of  BDV-specific  antibodies  in  cats  with  neurological 
disease  are  needed,  for  a  better  understanding  of  disease  development  in 
feline BD and for better advice to clinicians in making correct diagnosis. 
These studies should include cats from different regions of Sweden. 
Molecular Detection versus Serology 
Previous  results  indicated  that  naturally  infected  cats  did  not  develop 
antibody titers sufficiently high for serological diagnostics (Johansson et al., 
2002). Therefore, an rRT-PCR was developed for molecular detection of 
BDV (Paper I), and applied for diagnostic purposes (Papers II & IV). Even 
though a majority of the cats were positive for BDV-RNA (58% in Papers 
II & IV), it was only detected in samples from live animals in a few cases 
(32%; Paper II). Moreover, there was not a single clinical sample where the 
material was consistently positive, although blood was the most common 
one. Possible explanations for the low number of PCR-positive cats could 
be  low  viral  load,  due  to  the  nature  of  BDV  persistence  in  the  CNS, 
together  with  RNA  degradation  during  sampling  procedure  and  sample 
handling, as well as sequence dissimilarities. However, compared to other 
studies  of  feline  BD  (Kamhieh  &  Flower,  2006)  the  number  of  PCR-
positive cats was quite high (Papers II & IV), indicating high sensitivity of 
the developed rRT-PCR. Based on the results in Paper II, the value of 
rRT-PCR as a diagnostic method to confirm the clinical suspicion of feline 
BD is questionable, except for cats showing mild neurological signs, where 
most of the PCR-positive blood samples (3 out of 5) were found. 
IFA is a well-established serological method, commonly used to diagnose 
BD  (Herzog  &  Rott,  1980; Ludwig  et  al.,  1973),  even  though  it  is  less 
sensitive than ELISA (Bode et al., 2001). Recent studies have shown that a 
conventional BDV-IFA, using equine BDV as antigen, detects antibodies 
developed as a response to ABV infection in psittacine birds (Herzog et al., 
2010). These results indicate the validity of IFA even to diagnose infections 
of  more  divergent  Bornaviruses.  As  no  feline  BDV  strain  has  been 
completely sequenced, and only a few partial sequences have been reported, 
more  divergent  variants  of  feline  BDV  could  exist.  These  sequence 
dissimilarities  could,  as  previously  discussed,  explain  the  difficulty  of 
diagnosing  feline  BD  by  molecular  methods.  Likewise,  it  could  be  one 
explanation for why antibodies are detected in the absence of BDV-RNA, 
since antibodies towards divergent strains cross-react with the equine BDV 
antigen used in the IFA. Six of the cats were only sero-positive, whereas 
two were only PCR-positive, and seven were positive for both infection 
markers (Paper II).   55 
Overall, serology is a useful tool to guide the clinician when making the 
diagnosis of feline BD, especially in cats showing typical clinical signs. In 
addition, BDV rRT-PCR of blood samples could be helpful when cats are 
showing mild neurological signs. 
Papers II & IV – Immune Response in Feline BD 
In Paper IV, IFN-  mRNA expression was studied in cats with feline BD, 
and  compared  to  the  expression  in  cats  without  BDV-infection.  As 
previously discussed, not all cats were confirmed to harbor BDV-RNA in 
brain tissues. This study clearly showed that IFN-  is highly expressed in 
cats with feline BD, regardless of whether BDV-RNA could be detected or 
not, whereas non-diseased cats expressed no or low levels of IFN-  mRNA. 
Only one cat (cat V, Paper IV) was negative for BDV-infection markers, 
when samples other than brain tissues used for BDV-RNA detection, as 
well as serological data, are taken into account (Paper II). 
IFN-   is  an  important  antiviral  cytokine  of  the  adaptive  immune 
response, and a key player in viral clearance, especially in sensitive tissues 
such  as  the  CNS  where  cytolysis  is  unwanted  (Chesler  &  Reiss,  2002). 
Release of IFN-  not only takes place in acute infection, but can also be 
prolonged, even after the virus has been cleared (Rottenberg & Kristensson, 
2002). Thus, IFN-  can affect the brain without the presence of the virus. 
Previous studies show, that IFN-  can block BDV infection in some cell 
lines (Sauder et al., 2004), and also block BDV multiplication in tissue slice 
cultures (Friedl et al., 2004). In experimentally BDV-infected mice, IFN-  is 
necessary for viral clearance by CD8+ T cells (Hausmann et al., 2005), and 
in experimentally BDV-infected rats the IFN-  inducible protein IP-10 is 
highly expressed (Jehle et al., 2003; Sauder et al., 2000). Hence, IFN-  is an 
important player in the host immune response to BDV-infection.  
The importance of IFN-  in viral clearance can also be an explanation 
for why not all cats with feline BD are positive for BDV-RNA. It has been 
previously noted that cats with a high degree of inflammation are less likely 
to  be  positive  for  BDV-RNA  by  RT-PCR,  whereas  cats  with  milder 
inflammatory reaction are more frequently PCR-positive (Anna-Lena Berg, 
personal communication). However, BDV is still present in cats expressing 
IFN- , indicating mechanisms for evading this antiviral response by BDV. 
One such mechanism has been assigned to BDV P, which inhibits inducible 
nitric oxide synthase (iNOS) expression (Peng et al., 2007), induced by for 
example IFN- .   56 
The low viral load in cats, compared to horses, could indicate a more 
efficient  clearance  of  BDV  in  this  species.  Horses  usually  have  strong 
immunoreactivity for BDV-antigen, and the antigen expression co-localizes 
in the same brain regions as inflammatory changes (Gosztonyi & Ludwig, 
1984),  whereas  cats  have  weaker  antigen  expression  (Lundgren  et  al., 
1995a), with a similar distribution pattern as in horses (Anna-Lena Berg, 
personal communication). The IFN-  expression, or the activity of IFN- , 
could  be  different  between  species,  though  this  hypothesis  needs  to  be 
proven by for example comparative gene expression analyses. 
Some of the cats studied in Paper IV were also included in Paper II. 
Interestingly, cats with mild neurological signs had significantly higher IFN-
  mRNA expression compared to cats with severe neurological signs (Papers 
II  &  IV).  The  IFN-   expression  followed  the  degree  of  inflammatory 
reaction: lower IFN-  expression in cats with milder pathological lesions, 
and higher IFN-  expression in cats with severe pathological lesions. Cats 
with  mild  neurological  signs  had  moderate-severe  pathological  lesions, 
suggesting that a heavy inflammatory reaction does not necessarily lead to 
more severe clinical signs (Paper II). As BD is considered to be immune-
mediated  (Stitz  et  al.,  1995),  this  observation  is  very  interesting,  since  it 
indicates a more virus-induced effect in the development of clinical signs in 
feline  BD  than  previously  considered.  This  is  similar  to  what  is  seen  in 
experimental infection of newborn rats, where neurological signs, such as 
behavioral  changes,  can  be  seen  without  inflammation  (Gosztonyi  & 
Ludwig, 1995). Further indications of direct viral effects on pathogenesis are 
seen  in  transgenic  mice,  expressing  BDV  P  in  glial  cells,  which  induce 
neurological signs, similar to BDV-infection (Kamitani et al., 2003). Also in 
one cat, neurological signs were seen without inflammatory reaction, but in 
the presence of BDV (Berg & Berg, 1998), further suggesting direct effects 
attributed to BDV. Such direct effects could be BDV-host protein-protein 
interactions,  like  the  interaction  between  BDV  P  and  GABARAP, 
interfering  with  the  trafficking  of  GABA-R  to  the  cellular  membrane, 
which in turn could cause behavioral changes due to disturbances in the 
GABA neurotransmission (Peng et al., 2008). 
Paper III – Visualization of Phosphorylated BDV P and BDV-Host 
Protein-Protein Interactions 
Several protein-protein interactions between BDV and its host have been 
reported (Planz et al., 2009). In the study presented in Paper III, two cellular 
proteins  previously  demonstrated  to  interact  with  BDV  proteins  were   57 
visualized  in  cell  cultures  and  brain  tissues  by  the  use  of  in  situ  PLA. 
Furthermore, in situ PLA was also used for demonstration of phosphorylated 
BDV P, and compared to IHC staining of brain tissues of experimentally 
and naturally infected animals. 
Visualization of Phosphorylated BDV P 
Initially,  IFAs  of  persistently  BDV-infected  C6  cells  (C6BDV;  rat 
astrocytoma cell line) and IHCs of brain tissues were performed for BDV P, 
as well as host proteins, to evaluate the antibodies and protocols. In the IHC 
for BDV P, a rabbit polyclonal antibody was used (Johansson et al., 2002). 
Neurons of the infected animals had a strong staining for BDV P, whereas 
no specific staining was seen in the non-infected controls. 
In the in situ PLA for BDV P, a set of two primary antibodies was used. 
In addition to the rabbit polyclonal antibody used in the IHC, one mouse 
monoclonal antibody (Ludwig et al., 1993) was used. According to epitope 
mapping,  this  monoclonal  antibody  specifically  binds  to  phosphorylated 
BDV  P,  further  confirmed  by  determining  in  vitro  phosphorylated 
recombinant BDV P in an antigen ELISA (Bode, 2008). Thus, the in situ 
PLA for BDV P will selectively detect phosphorylated BDV P. 
A similar distribution pattern was seen when using both IHC staining 
and  in  situ  PLA,  but  comparatively  fewer  BDV-positive  cells  were  seen 
using in situ PLA. This difference could be contributed by the need for dual 
recognition  in  the  in  situ  PLA,  and  corresponds  to  the  phosphorylation 
pattern  of  BDV  P.  Upon  phosphorylation  by  PKC ,  BDV  P  down-
regulates  the  viral  RNA-dependent  RNA-polymerase  (L)  (Schmid  et  al., 
2007). However, phosphorylated P is important for the efficient spread of 
BDV  (Schmid  et  al.,  2010),  and  competes  with  endogenous  PKC  
substrates,  thereby  affecting  neuronal  plasticity  (Prat  et  al.,  2009).  The 
phosphorylation of BDV P seems to have dual effects on the viral life cycle: 
replication control, which could be of importance in persistent infection, 
and promoting viral dissemination. The exact mechanisms for the latter are 
not known. Further studies are also needed for investigating any differences 
in  specific  distribution  of  phosphorylated  P  during  different  stages  of 
infection, regarding brain regions and cellular compartments. 
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Figure  14.  Detection  of  phosphorylated  BDV  P  in  cats  using  in  situ  PLA.  The  upper 
micrograph shows a cat with feline BD (cat D, Paper I), and the lower micrograph shows a 
non-infected control cat. More signals are seen in the diseased cat compared to the control. 
Photos: Karl-Johan Leuchowius. 
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The BDV P in situ PLA was also used in cats, and preliminary data shows 
the presence of phosphorylated BDV P in a cat with feline BD, and a few 
signals in a cat without this disease (Figure 1). Due to the need for dual 
recognition, in situ PLA is more selective than IHC, and could be a useful 
tool  to  increase  specificity  when  specific  IHC  staining  is  difficult  to 
distinguish from the background. 
Visualization of BDV-Host Protein-Protein Interactions 
The BDV-host protein-protein interactions studied in Paper III were the 
interactions between BDV N/P and Cdc2 (Planz et al., 2003), and BDV P 
and HMGB1 (Kamitani et al., 2001), previously reported. By the use of in 
situ PLA, these interactions could be visualized initially in C6BDV cells, 
where the signals most commonly were seen inside the nuclei, and then also 
in brain tissues of experimentally (Cdc2 and HMGB1) and naturally (Cdc2 
only) infected animals. 
Previously, both BDV N and P have been demonstrated to interact with 
Cdc2,  although  it  is  N  that  interferes  with  the  functions  of  Cdc2  by 
reducing the proliferation rate in transfected and infected cells (Planz et al., 
2003). Therefore, it did not come as a surprise that BDV N, as well as BDV 
P interactions with Cdc2 could be visualized in BDV-infected cells. For 
HMGB1,  BDV  interferes  with  the  multiple  functions  of  this  protein 
through interaction by P and not N (Zhang et al., 2003; Kamitani et al., 
2001). On the other hand, BDV N and P interact with each other (Berg et 
al., 1998b); and thus, BDV N-HMGB1 interactions visualized in C6BDV, 
most likely originate from indirect interactions via BDV P. 
In tissues, BDV N-Cdc2 interactions were detected in scattered neurons, 
both in an experimentally infected rat and in a naturally infected horse. As 
this interaction slows down the proliferation rate of cells (Planz et al., 2003), 
BDV could use this to promote the establishment of a (persistent) infection, 
especially in dividing cells. 
The interaction between HMGB1 and BDV P was detected only in the 
experimentally infected rat. This rat was sacrificed rather early in infection 
(30  days  post  infection),  when  BDV  is  likely  to  be  in  the  process  of 
establishing persistence in the studied regions of the CNS. Probably, the 
interference  of  the  pro-inflammatory  functions  of  HMGB1  is  more 
important  early  in  the  course  of  infection  than  at  the  end-stage,  when 
persistence  already  is  established.  The  naturally  infected  horse  showed 
typical  signs  of  BD,  loss  of  weight,  ataxia,  circling  movement,  and 
depression, suggesting a longer duration of infection. HMGB1 is expressed 
at different levels depending on age, at least in the mouse, where younger   60 
animals have comparatively higher expression (Enokido et al., 2008; Guazzi 
et al., 2003). The horse included in this study was 12 years old at euthanasia, 
and the rat was four months old when sacrificed. Even though the rat was 
adult,  the  horse  should  be  regarded  as  comparatively  older.  From  this 
material it is not possible to draw any conclusions about species differences 
in  BDV  P-HMGB1  interactions.  Hence,  duration  of  infection,  age 
differences,  but  also  differences  in  infection  route,  could  be  explanations 
behind the absence of signals in the horse.  
Paper  III  represents  the  first  study  where  virus-host  protein-protein 
interactions have been visualized in situ in infected cell cultures and tissues 
by the use of in situ PLA.   61 
Conclusions 
This  thesis  has  focused  on  BDV  and  its  hosts,  by  developing  different 
techniques  to  study  presence  of  infection  markers  (BDV-RNA,  BDV-
antigen  and  BDV-specific  antibodies),  and  by  studying  BDV-host 
interactions. Based on these studies, and the experiences gained, the main 
conclusions are: 
 
•  Real-time RT-PCR is a highly sensitive and specific assay for detection 
of BDV-RNA, as down to 10 copies of the gene targets per reaction 
can be detected. Three reference strains, including the most divergent 
strain No/98, as well as five feline field strains, and a feline BDV isolate, 
were detected, indicating a broad range of detection. 
 
•  In  most  cats  with  typical  clinical  signs  of  feline  BD,  and  with 
characteristic  pathological  lesions,  at  least  one  BDV-infection  marker 
(BDV-RNA and/or BDV-specific antibodies) could be detected. The 
most common marker is the presence of antibodies in serum, which 
were detected in 81% of cats with feline BD, compared to 16% of a 
reference population at high risk. Serology is therefore the most helpful 
diagnostic  tool  when  presented  with  a  clinical  case  of  feline  BD.  In 
addition,  molecular  detection  of  BDV  in  blood  can  aid  in  the 
confirmation of BD in cats with mild neurological signs. 
 
•  In situ PLA is a useful tool to study the presence of BDV-antigen, and 
increases the selectivity by the use of dual recognition. This assay can be 
particularly useful for post-mortem diagnostics when antigens are hard to 
distinguish  from  background  signals  in  conventional  IHC,  thus 
increasing the need for highly specific detection methods. 
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•  BDV proteins interact with host cellular proteins of infected animals, 
most  likely  interfering  with  important  functions  in  favor  of  virus 
persistency.  
 
•  Cats with BD express IFN- , and this expression is higher in animals 
showing mild neurological signs, in which moderate-severe pathological 
lesions are also more common. Together, these findings point to a more 
direct BDV-induced effect in the development of clinical signs in feline 
BD than has been considered previously. 
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Future Perspectives 
Borna disease virus is an intriguing infectious agent, and after a century of 
research  concerning  different  aspects  of  this  pathogen  and  the  diseases  it 
causes, many questions are still to be answered. From a clinical point of 
view,  better  and  more  secure  diagnostic  methods  are  needed,  as  well  as 
increased knowledge of how to interpret diagnostic results, and what to do 
when a diagnosis is made. Further studies to enlighten the infection biology, 
as well as the molecular epidemiology, of BDV are also needed. 
Are the typical clinical signs enough to determine whether a particular 
cat suffers from feline BD? Or is a serological test needed for confirmation? 
If the test is negative, does this mean that the cat does not have the disease? 
If a cat showing atypical clinical signs carries antibodies, how likely is the 
clinical diagnosis to be feline BD? Even though these questions have been 
partially answered in this thesis, further studies are needed, such as sero-
epidemiological  studies  of  cats  from  different  geographical  regions  of 
Sweden, and with different housing, as well as more concentrated studies of 
cats  showing  different  neurological  signs.  Other  species,  like  horses  and 
dogs,  should  also  be  included,  since  BDV-infection  is  known  in  these 
species in Sweden as well (unpublished data; Berg et al., 1999a; Berg et al., 
1998b). 
Even if a confident diagnosis can be made, is that of importance if the 
outcome  is  still  euthanasia,  based  on  bad  prognosis  and  animal  welfare 
concerns? Other diseases could be similar to feline BD clinically, and thus a 
confirmation of the diagnosis is important. Once a confident diagnostic test 
is available, evaluations of different treatments would be necessary. In horses 
with BD, antiviral therapy using amantadine is reported to be favorable in 
several cases (Dieckhöfer, 2008; Dieckhöfer et al., 2004). This treatment has 
been used in cats as well, and in at least one case the cat got better, although 
side effects were present (Stina Viktorsson, personal communication). This   64 
cat  was  determined  as  positive  for  BDV-RNA  in  blood  by  rRT-PCR 
(unpublished data), although unfortunately it was not possible to follow up 
this  case  after  treatment.  Another  therapy  used  in  cats  is  corticosteroid 
treatment, which seems to be beneficial, especially if it is introduced at an 
early stage of the disease (Berg, 1999), although the effect is often seen only 
temporarily (Karin Hultin Jäderlund, personal communication). However, 
even  if  immunosuppressive  treatments,  such  as  corticosteroid  therapy, 
reduce the inflammatory response to BDV-infection, and hence immune-
mediated  clinical  signs,  the  immunosuppression  could  lead  to  higher 
replication of virus. A thorough evaluation of different therapies of feline 
BD  would  be  profitable  for  investigating  whether  this  disease  could  be 
treated. 
Feline  BD  has  mostly  been  reported  from  Sweden,  though  there  are 
studies from other parts of the world as well, indicating a wide geographical 
distribution of this disease (Kamhieh & Flower, 2006). Recently, a similar 
neurological disorder of unknown etiology was reported from the United 
Kingdom (De Risio et al., 2008), where BDV-infections in cats and a horse 
have been demonstrated (Priestnall et al., 2011; Reeves et al., 1998). In these 
so-called “robotic cats”, clinical signs are similar to those presented in Paper 
II. Some of these cats were investigated for the presence of BDV-infection 
markers,  although  no  such  markers  were  detected.  It  would  be  worth 
increasing  the  search  for  BDV-infection  markers  in  these  cats,  possibly 
including detection systems for more divergent strains like ABV. Serological 
evidence for BDV-infection in large felids (lions) was recently reported from 
Poland  (Czujkowska  et  al.,  2011).  However,  these  findings  need  to  be 
further  confirmed  by  other  methods.  Thus,  epidemiological  studies, 
including  molecular  epidemiology,  for  neurological  disorders  similar  to 
feline BD are needed. 
Different natural reservoirs for BDV have been discussed, though there 
are arguments for direct spread of BD in horses as well, because of the high 
sero-prevalence. The spread of BDV to different domesticated species could 
be variable, depending on housing and feeding preferences. Hypothetically, 
direct spread could be of more importance in herbivores, such as horses and 
sheep, whereas carnivores, such as dogs and cats, need to feed on infected 
prey to become infected. If this hypothesis could be confirmed, it would be 
an explanation for why BDV-infection in cats and dogs is not as frequently 
reported as in herbivores. Cats and dogs could in this case be regarded as 
accidental hosts, when preying on infected herbivores like rodents.  
In other members of the order of Mononegavirales, the Marburg and Ebola 
viruses, it has been speculated that these viruses are originally arthropod or   65 
plant viruses transmitted to animals when they either feed on the plants or 
are bitten by the insects (Monath, 1999). Interestingly, the gene of BDV L 
has  the  most  genetic  similarity  with  a  plant  virus  belonging  to  the 
Nucleorhabdoviruses, the only genus within the same order (besides BDV) to 
replicate inside the nucleus of infected cells (Pringle, 2005). Thus, although 
highly  speculative,  plant  or  insect  viruses  could  be  the  ancient  origin  of 
BDV, and wild herbivores, like rodents, could have acted as mixing vessels. 
This  hypothesis  would  be  interesting  to  follow  up,  to  find  out  whether 
there  is  a genetic  relationship  between  BDV  and  RNA-viruses  of  plants 
and/or arthropods, and also to follow up serological evidence of BDV in 
wild rodents (Kinnunen et al., 2007) by molecular characterization of such 
viruses. For such studies, viral metagenomics could be useful, where the 
global  viral  flora  can  be  detected  by  sequence-independent  methodology 
(Blomström, 2011), in order to find new, divergent BDV strains or BDV-
like  agents.  In  this  context,  the  recent  findings  of  the  genetically  more 
divergent ABV are also interesting. 
There  is  limited  or  rather  poor  information  available  concerning  the 
molecular epidemiology of feline strains of BDV, and there is a great need 
for characterizing these strains further for greater knowledge. For example, 
are these strains more similar to ABV, than previously considered? Because 
of the low viral load in cats, these kinds of studies are troublesome. During 
the work for this thesis, we have tried to isolate virus from naturally infected 
cats in different cell lines, though so far these efforts have failed. At least one 
BDV-strain isolated from cats would be helpful for further characterizing 
feline  BDV  by  full-genome  sequencing.  Also,  the  viral  metagenomic 
approach could be useful, to detect novel BDV strains, or other pathogens, 
coinciding in feline BD. Co-infections could be one explanation for why 
not all cats carrying BDV-specific antibodies develop clinical disease. Host 
factors, like different genetic background, could be another explanation for 
this observation.  
The  pathogenesis  of  BD  in  different  species  still  needs  further 
elucidation.  The  cellular  receptor  for  BDV  when  entering  cells  in  the 
olfactory  epithelium  is  still  unknown,  and  inside  the  CNS  the  kainate 
receptor has been proposed to be involved in viral entry (Gosztonyi, 2008). 
By what mechanisms the RNP is transported from the first site of entry to 
the  CNS  is  also  unknown,  although  most  likely  the  macromolecular 
transport  systems  within  neural  cells  are  used.  The  direct  viral-induced 
effects  contributing  to  neurological  signs  are  also  interesting  subjects  for 
further studies. In all of these investigations, the application of in situ PLA 
could be a practical tool to study BDV-host protein-protein interactions in   66 
brain  tissues  of  experimentally  and  naturally  infected  animals.  Further 
cytokine mRNA expression analyses in cats with feline BD, accompanied 
by  comparative  studies  of  BDV  infection  in  other  species,  could  also 
contribute to a better understanding of the host immune responses, as well 
as viral evasion mechanisms, in this intriguing disease. 
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Populärvetenskaplig sammanfattning 
Vingelsjuka hos katt är en neurologisk sjukdom som karakteriseras av vinglig 
gång  och  beteendeförändringar.  Denna  sjukdom  orsakas  av  ett  virus, 
bornavirus, som ger en kvarstående (persistent) infektion av celler i centrala 
nervsystemet. Bornavirus-infektioner har varit kända sedan början av 1900-
talet hos häst och får i Centraleuropa, men det var först i mitten av 1990-
talet som det upptäcktes att vingelsjuka hos katt, beskriven första gången i 
början av 1970-talet, orsakas av bornavirus. Däremot har det hittills varit 
svårt att ställa diagnosen vingelsjuka eller felin bornasjuka hos levande katter. 
Målet med denna avhandling var att utveckla nya metoder för att påvisa 
virus, i syfte att förbättra den nuvarande diagnostiken. Ett annat mål var att 
öka kunskapen om interaktioner mellan virus och värd, för att bättre förstå 
hur sjukdom hos djur infekterade med bornavirus uppkommer. Det senare 
gjordes  med  molekylära  tekniker,  där  virusproteinerna  studerades,  särskilt 
med avseende på hur de binder till värdens proteiner och därmed påverkar 
deras normala funktion.  
I  den  första  studien  utvecklades  en  molekylärdiagnostisk  metod  för 
påvisande av virus-nukleinsyra. Denna metod är mycket känslig, eftersom 
endast  10  kopior  av  virusets  arvsmassa  kunde  detekteras.  Dessutom  är 
metoden  bred  i  sin  detektionsförmåga,  eftersom  den  kunde  påvisa  olika 
referensstammar av bornavirus, liksom virus från katter med vingelsjuka. I 
nästa  studie  användes  denna  metod,  men  även  en  serologisk  metod  för 
påvisande av antikroppsförekomst i blodserum, för att utvärdera vilken eller 
vilka metoder som är bra för att bekräfta bornavirusinfektion hos katter med 
vingelsjuka. Det visade sig att antikroppar i serum är en mycket bra och 
säker hjälp vid diagnostik av vingelsjuka, i och med att 81 % av katterna 
med kliniska symtom på vingelsjuka hade antikroppar, jämfört med endast 
16 % hos en referensgrupp av katter utan dessa symtom.   68 
I den tredje studien användes en ny metod (så kallad närhetsligering) för 
att  se  interaktioner  mellan  virusets  protein  och  värdorganismens  protein. 
Sådana interaktioner kunde ses i experimentellt infekterade celler, men även 
för  första  gången  i  en  experimentellt  infekterad  råtta  och  i  en  häst  med 
bornasjuka. Sannolikt orsakar dessa interaktioner störningar hos värddjurets 
normala funktioner, vilket underlättar för viruset att etablera en långvarig 
infektion och gömma sig för immunsvaret. 
En  del  i  detta  immunsvar  är  signalmolekyler  som  kallas  interferoner 
(IFN),  av  vilka  IFN-   är  särskilt  viktig  för  att  minska  mängden  virus  i 
hjärnan. I den sista studien studerades uttrycket av IFN-  hos katter med 
vingelsjuka. Det visade sig att detta uttryck är kraftigt vid vingelsjuka och 
kraftigast hos katter med milda kliniska symtom. Denna grupp av katter har 
också de allvarligaste sjukliga förändringarna i hjärnan. Sammantaget pekar 
det mot att bornavirus kan ha en mer direkt påverkan i utvecklingen av de 
symtom som ses vid vingelsjuka än vad man tidigare trott. 
 Fler  framtida  studier  behövs  för  att  ytterligare  klargöra  sjukdoms-
mekanismerna bakom denna mystiska sjukdom, samt för att få mer kunskap 
om hur sjukdomen sprids och om den kan behandlas. 
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